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The inherent properties of protein therapeutics (e.g. high molecular weight, charged, 
conformationally dependent) has historically limited their administration to parenteral routes 
which presents new challenges to their controlled delivery.  Hydrogel and nanoparticle drug 
delivery systems can parenterally deliver a wide variety of drugs in a controlled manner while 
sustaining their therapeutic efficacy. Nanogels, formed from amphiphilic polymers, combine the 
unique and tunable properties of hydrogels and nanoparticles into one drug delivery system and 
have the potential to drastically improve the clinical applicability of protein therapeutics delivered 
subcutaneously. 
Hyaluronic acid, a ubiquitous polysaccharide of the extracellular matrix often used in drug 
delivery applications,  was hydrophobically functionalized by the addition of glycine-modified 
vitamin E (-tocopherol) to form a self-assembling nanogel (HAtoco). The characterization of 
HAtoco was further developed by modifying its molecular weight and tocopherol substitution 
towards an optimum 33 kDa backbone with a 10mol% substitution. Physical and chemical 
characterization of the optimum HAtoco demonstrated its polydisperse effective size, stable 
colloidal and chemical stability and continued biodegradability by the endogenous enzyme 
hyaluronidase. In addition, HAtoco doubled the in vitro release half-life of three model proteins 
(BSA, RNase, Lysozyme) and the in vivo release half-life of the clinical protein therapeutic 
Coversin when delivered subcutaneously to mice. Structural studies of HAtoco bound Coversin 
demonstrated destabilization of the protein upon adsorption, but released Coversin from the 
HAtoco nanogel demonstrated complement inhibition for at least 73 hours in vitro. Overall, 
HAtoco has demonstrated the ability to bind protein therapeutics in a reversible manner capable 
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Chapter I: Introduction 
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1.1 Advantages to Modified Release Strategies of Pharmaceuticals 
Medicines  can be considered  drug delivery systems (DDS) which strive to deliver a 
desired effect in a safe, efficient, reproducible and convenient way.1 Although the medicinal 
application of slow release coatings has been in use since twelfth century China2, the modern 
western design of modified or slow release systems began in the 1950’s3 with the introduction of 
Spansule by Smith-Kline & French.4 Prior to the introduction of Spansule, all medicines 
constructed in pill or capsule formulations  released the drug or active pharmaceutical ingredient 
(API) immediately upon dissolution of the outer enteric coating. No mechanism was intentionally 
implemented to modify or control the release of drug.3 Conventional medicines designed in this 
manner generally exhibit fast absorption, systemic exposure and subsequent onset of the intended 
pharmaceutical effect.  The profile of drug release from a dosage form can be deliberately modified 
to achieve a variety of objectives, from therapeutic targets to patient convenience. A modified-
release drug product is a dosage mechanism that alters the timing, rate or location of release of the 
active pharmaceutical. These products include extended release, delayed release and targeted 
release. Modified-release drug products can obtain these drug profiles from a number of strategies 
including enteric coating and prodrug modification for orally delivered drugs, depot suspensions 
for parenterally delivered drugs. Selection and design of a modified-release form must take into 
account the intended route of administration and the physicochemical, pharmacokinetic and 
pharmacodynamic properties of a drug candidate.1, 5 
The ultimate goal of an effective drug delivery strategy is to maintain an appropriate 
therapeutic concentration of an active drug form for the appropriate duration of time and in the 
appropriate location. For acute maladies requiring fast action, conventional medicines generally 
deliver drug through a single dose with immediate release to the intended therapeutic location at 
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concentrations sufficient for therapeutic effect while avoiding drug-induced toxicity. The area 
between an ineffective concentration and toxic concentration is known as the therapeutic window 
(Figure 1.1).6 In contrast, chronic conditions often require a sustained period of therapeutic 
efficacy to avoid relapse of symptoms. Multi-dose regimens can sustain the desired 
pharmacological effect. This strategy can lead to wide variations in drug levels during treatment 
and requires strict patient compliance for  the desired pharmacotherapeutic outcome. Modified-
release drug strategies are used to avoid pharmacokinetic and compliance complexities associated 
with frequent dose regimens. These strategies incorporate the required multiple doses for treatment 
into a drug sustaining those concentrations within the therapeutic window for the desired duration 
(Figure 1.2).6  
Spansule4 was the first sustained-release formulation technology to maintain the 
therapeutic drug concentration for 12 hours by incorporating coated and uncoated drug beads 
within a capsule. This approach allowed differential dissolution of drug and thus exposure by 
altering access to GI fluids.7 Since its release, the field of drug delivery has expanded 
exponentially, substantially impacting the pharmaceutical industry. Early research successfully 
developed many models of oral sustained release systems still used today. More recently, efforts 
to design novel DDS which can overcome biological barriers has become an area of heightened 
focus.8 Today, delivery systems such as transdermal patches, microparticles, nanoparticles, 
inhalers and antibody-drug conjugate products have cumulative annual revenues greater than $100 
billion9 and most importantly have improved countless lives. 
It is the task of a drug delivery scientist to evaluate the proper route of administration and 
dosage form of a medicine based on the desired therapeutic target and the physicochemical 
properties of the drug. This chapter covers the challenges and opportunities presented by the 
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delivery of protein therapeutics, including advances in the development and examination of novel 
drug delivery platforms to control their release profiles. Particular attention is given to the use of 













Figure 1.1: Single dose absorption and elimination vs. multi-dose regimen. © 2016 John Wiley  
& Sons, Inc. Used with permission without changes from Barich, D. H.;  Zell, M. T.; Munson, E. 
J., Physicochemical Properties, Formulation, and Drug Delivery. Drug Delivery: Principles and 
Applications, Second Edition. Edited by Binghe Wang, Longqin Hu, and Teruna J. Siahaan. 






Figure 1.2: Modified-release drug delivery strategies to alter drug exposure profiles.  © 2016 John 
Wiley  & Sons, Inc. Used with permission without changes from Barich, D. H.;  Zell, M. T.; 
Munson, E. J., Physicochemical Properties, Formulation, and Drug Delivery. Drug Delivery: 
Principles and Applications, Second Edition. Edited by Binghe Wang, Longqin Hu, and Teruna J. 




1.2 High Prevalence of Biologics 
Over the past four decades, macromolecule drugs known as biologics have become a 
significant portion of the medicines approved each year within the pharmaceutical industry. These 
biopharmaceutical drugs can include peptides, recombinant proteins, enzymes, antibodies, 
antibody drug conjugates and many more. To date, over 260 novel biological therapeutics have 
been approved for human use for over 230 indications.10 In 2018, 59 new medical entities (NMEs) 
were approved by the FDA, and 17 of the approved NMEs were biological license applications 
(BLAs). Since 2010, 24% of all NMEs approved by the FDA have been biologics (Figure 1.3) 
with total sales of biopharmaceuticals reaching $188 billion globally in 2017.11, 12 Developmental 
pipelines have been similarly affected, with biologics encompassing nearly 20% of all drugs 
developed in 2013.13 
 
1.3 Challenges to the formulation and delivery of protein therapeutics 
The increasing development of biopharmaceuticals is largely due to their inherent 
advantage in specificity and potency compared to small molecule drugs arising from their 
increased structural complexity. However, these complexities have led to recognizable challenges 
in their formulation and deliverability.13 Significant physicochemical differences exist between 
proteins and small molecule therapeutics particularly with respect to their molecular weight, 
functional group diversity including ionization and hydrophilic/lipophilic balance and their general 












Figure 1.3: FDA approvals of novel molecular entities (NMEs) and biological drug applications 
(BLAs) since 1993.12 © 2019 Springer Nature Publishing AG. Used with permission without 








1.3.1 Protein Structure 
Proteins are composed primarily of 20 common amino acids linearly polymerized by 
peptide (amide) bonds. This linear sequence of amino acids is known as a polypeptide. Wide 
variability exists within the physicochemical properties of individual amino acid side chains. 
Variabilities include charge, hydrophobic character, hydrogen-bonding capacity, molecular weight 
and flexibility which significantly contribute to the higher ordered structure and dynamics of the 
protein.15 Proteins form four higher ordered levels of structure: primary, secondary, tertiary and 
quaternary. The protein primary structure is defined by the linear arrangement of amino acids 
forming the polypeptide backbone. Secondary structures describe local conformations due to 
hydrogen bonding initiated between carboxyl oxygens and amide nitrogens of spatially 
neighboring amino acids backbones. Secondary structure spatial arrangements like  the -helix, -
sheet and -turn are commonplace in structurally elucidated proteins.16 Tertiary structural 
arrangements are a result of the cumulative coalescence of interactions from secondary structures, 
side chain hydrophobicity, hydrogen bonding, electrostatic interactions, van der Waals forces and 
disulfide bridging, ultimately determining the protein’s three dimensional form. Hydrophobic 
interactions are substantially impactful during the development of tertiary structure due to 
hydrophobic side chain water exclusion through the formation of a hydrophobic protein core.17, 18 
The highest ordered structure, quaternary structures, describe the intermolecular interactions 
between tertiary domains of two or more proteins, which can lead to an array of multimers forming 
in solution.17  
The inherent higher ordered structures of proteins and their critical contribution to the 
heightened specificity of protein therapeutics over small molecules increases the importance of 
developing a formulation preserving these structures. Chemical degradation of the amino acid 
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backbone and sides chains through mechanisms such as deamidation and oxidation can lead to 
decreased potency and/or increased immunogenicity.19 Significant attention is also paid to the 
physical aspects of formulations which may lead to the loss of protein function such as moisture 
or temperature driven protein aggregation and conformational alterations.20  
 
1.3.2 Physiological barriers to protein delivery 
The degree of physiological barriers impeding the effective delivery of proteins depends 
on both the method of delivery and site of action. Passage of drugs across cellular barriers generally 
occurs through four pathways: paracellular, transcellular, active transport or endocytosis. The 
route in which drugs are able to permeate these biological barriers is highly influenced by its 
polarity, ionization, physical size and conformation. Paracellular transport is largely restricted to 
small molecular weight solutes and peptides of less than 8 Å in diameter (ca. 180 Da or 1-2 amino 
acids).21  This is due to the presence of tight junctions and is therefore not suitable for the 
permeation of normally high molecular weight proteins.22 In order for drugs to passively transverse 
the membrane lipid bilayer, they must possess a similarly small size, but also significant lipophilic 
character. The lipophilic characteristics and size exclude a majority of protein therapeutics. 
Proteins which generally are restrained by their high molecular weight and hydrophilic/charged 
surfaces are therefore limited to active, facilitative or endocytic transport mechanisms in order to 
cross cellular barriers. These transportation processes occur through interaction with 
transmembrane proteins which assist in the traversing of the lipid bilayer down concentration 




1.3.3 Oral delivery of proteins 
Orally delivered medicines comprise the majority (62.02%)24 of currently marketed 
pharmaceutical products (Figure 1.4) within the US due to their ease of administration and 
sustained delivery which lead to higher patient compliance.25 Oral dosage forms are  generally less 
expensive to produce without required sterile manufacturing condtions.26  Although viewed as the 
most sought-after route of delivery, oral administration of biopharmaceuticals has been historically 
challenging.27, 28 The oral bioavailability of proteins is limited, typically less than 1-2%. It is 
limited for many reasons, including chemical degradation in the shifting pH of the gastrointestinal 
tract, proteolytic degradation and limited permeation through mucosal layers and across the 
intestinal endothelium due to their inherent charge and size.25, 29, 30 Outside of live-attenuated 
vaccine products, to date only two peptide-based drugs have been approved for oral delivery. The 
approved drugs are desmopressin and cyclosporin, each with bioavailabilities of less than 30% 
despite their relatively small sizes, 1069 Da and 1203 Da, respectively.31 Other delivery routes 
such as nasal32, pulmonary33, buccal and vaginal have been explored for protein therapeutics with 


















Figure 1.4: (a) Distribution of administration route for currently approved FDA pharmaceutical 
products. (b) Comparison of new (inner circle) and generic (outer circle) drug administration route 
distributions. © 1996-2019 MDPI. Used with permission without changes from Zhong, H.; Chan, 
G.; Hu, Y.; Hu, H.; Ouyang, D. A Comprehensive Map of FDA-Approved Pharmaceutical 







1.3.4 Parenteral delivery of proteins 
Due to the challenges presented by the oral delivery of protein therapeutics, the vast 
majority of approved biologics are parenterally delivered through intravenous, subcutaneous or 
intramuscular injection. Direct injection avoids many of the barriers associated with oral delivery 
leading to higher bioavailability and lower manufacturing costs. Unlike orally delivered 
therapeutics, parenteral injections are able to avoid first-pass hepatic and gastrointestinal 
metabolism leading to longer circulating half-lives and subsequent effector functions.35, 36 
Although improvements in bioavailability of biologics through parenteral delivery makes their 
development feasible, many disadvantages still exist.  
 
1.3.5 Burden of parenteral administration on patients and the medical system  
Half of the adults worldwide and about 8% of children are estimated to have a chronic 
condition requiring medical treatment.37 An estimated 50% of patients requiring long-term therapy 
for a chronic illness exhibit some form of non-adherence to their prescribed medication regimen.38, 
39 Traditionally, parenterally delivered biologics require the use of needles to administer, which 
many patients find painful leading to poor patient compliance.40, 41 Estimated costs of medication 
non-adherence within the US range from $100 to $290 billion annually.38 Parenteral 
administration, particularly intravenous, requires a trained professional to safely administer which 
can create barriers to compliance. 42 In addition, many proteins have relatively short half-lives in 
circulation which leads to multiple visits to a medical professional for administration increasing 
the overall cost to the patient, decreases compliance and stress on the medical system. 
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1.3.6 Benefits of at-home or self-administration programs on patient 
compliance and the overall healthcare market 
Health care spending in the United States grew 3.9% to $3.5 trillion or $10,739 per person 
in 2017, reaching 17.9% of the gross domestic product (GDP).43 Compared to the top ten GDP 
nations, the US spends nearly twice as much on health care with the cost of labor and products as 
a significant contributing factors.44 Treatment of chronic conditions, which can require regular 
hospital visits,  accounts for nearly 75% of total health care spending.45 In addition to legislative 
efforts such as the adoption of the Affordable Care Act (ACA) to reduce overall healthcare 
spending and increase focus and funding on disease prevention efforts, many hospital systems 
have proposed and implemented home-based care programs. These programs facilitate clinicians 
administering treatment to acutely ill patients within their own home.46, 47 These programs 
drastically reduce the capital resources required for patient treatment when compared to in-hospital 
care. However, these programs place burden on clinicians, who are unable to see as many patients 
and are often not reimbursed for travel time. A similar program analyzing the cost savings of an at 
home medical professional injection compared to clinical-setting administration of the 
chemotherapeutic bortezomib resulted in a 16.5% cost savings.48 In continuation of these efforts 
to reduce the medical costs associated with clinical-setting administration of drugs, educating 
patients on disease self-management, including drug administration, has been proposed.45 This 
type of self-care has been shown to be effective in multiple chronic diseases, most notably the 
treatment of type 1 diabetes. Patients are trained to monitor their own blood sugar levels and on 
proper administer insulin injections subcutaneously when needed.49 At home, self-administration 
of biotherapeutics is also common practice for chronic diseases like rheumatoid arthritis, primary 
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immunodeficiency and multiple sclerosis.50 Many  subcutaneous oncology therapies are also 
currently under consideration.51, 52 
 
1.3.7 Subcutaneous injections as a desirable alternative to other parenteral 
delivery routes 
 Clinical settings required for safe and effective injections of many biologics have been 
shown to add to overall treatment costs and are a resource burden on the healthcare system, 
healthcare providers and patients.50 A study of overall administration time of trastuzumab when 
delivered subcutaneously instead of through intravenous (i.v.) infusion showed a decrease in 
duration of injection from 90 minutes to 5 minutes on average.53 In addition, use of subcutaneous 
injections in place of i.v. administration may reduce the risk of systemic infections.54 Intramuscular 
(i.m.) injections have been implemented to some degree for the administration of many 
biopharmaceuticals. However, the depth of skeletal muscle a 1 to 2 inch needle is required leads 
to an increased potential for pain due to muscle damage or nerve contact. The risk factors 
associated with the depth required for i.m. injections also makes administration by trained 
professionals in a clinical setting a requirement.55  
As a viable alternative to traditional intravenous or intramuscular delivery of biologics, 
subcutaneously delivered drugs have presented several advantages including improved patient 
compliance, stronger potential for self-administration and subsequently reduced healthcare 
costs.56-58 For these reasons, the global market of subcutaneously delivered biologics is projected 
to continue grow over the coming years.56 Overall, increased approvals of biopharmaceuticals 
coupled with the inherent physicochemical properties which limit their oral bioavailability has led 
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the biotechnology industry to explore subcutaneous delivery as a viable, convenient and cost-
effective means to parenterally administer these unique medicinal products. 
 
1.4 Subcutaneous anatomy and physiology 
Subcutaneous injections deliver drug product into the interstitial space located below the 
dermis known as the hypodermis (Figure 1.5).59 The main structural components of the 
hypodermis extracellular matrix (ECM) include collagen and glycosaminoglycans  like hyaluronan 
(hyaluronic acid, HA).60 Collagen, the most abundant protein in the body of mammals, forms a 
fibrous network critical for mechanical stability of the ECM.61 HA is a lineaer anionic 
polysaccharide of generally high molecular weight (up to 2000 kDa)62 and concentrations (1g per 
100g wet tissue)63 in the subcutaneous tissues. HA has been proposed to serve as a viscosity 
modified lubricant and is readily enzymatically degraded with a tissue half-life of 0.5 to 3 days.62 
The structure and physiology of the subcutaneous tissue can vary greatly between species and 
locations within the body which likely contributes to differences in absorption profiles and 











Figure 1.5: Subcutaneous injection with anatomy of skin. © 2015 RCN Publishing Ltd. Used with 
permission without changes from Ogston-Tuck, S., Subcutaneous injection technique: an 
evidence-based approach. Nurs Stand 2014, 29 (3), 53-8. 
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1.5 Pharmacokinetics of subcutaneously delivered biologics 
One of the most pressing challenges to the sustained delivery of biologics via intraveneous 
administration are the short biological half-lives ranging from minutes to hours which are often 
exacerbated by fast enzymatic degradation or renal clearance.34 Subcutaneously delivered proteins 
can exhibit a range of bioavailabilities and release profiles depending on their physicochemical 
properties and the given formulation.60, 64, 66 The bioavailability of monoclonal antibodies (mAbs) 
injected subcutaneously in the clinical-setting ranges from 50-85%.31 Following subcutaneous 
injection, protein therapeutics reach systemic circulation either through continuous blood 
capillaries or through lymphatic vessels if greater than 16-20 kDa.67, 68 The determinants of 
absorption for biotherapeutics following subcutaneous delivery is unclear. Absoroption kinetics 
are believed to be governed by diffusion rates of the biotherapeutic from the injection site and the 
convective interstitial flow to the site of absorption.31 Protein therapeutics, like all drugs, are not 
delivered solely as the active ingredient, but often with a complex formulation of buffers, 
excipients and stabilizers. These act to enhance the shelf-stability of a pharmaceutical and enable 
a more efficient delivery to the intended target. Upon injection, proteins transition from conditions 
in which they are formulated to those of the native interstitial environment.66 Low bioavailability 
conditions may form due to interactions with components of the ECM, uptake within circulating 
immunological cells or foreign bodies  like granulomas developing in response to non-native 
polymeric formulations.31, 69-71 Effects on biopharmaceutic stability, activity and transportive 
properties to changes in ionic composition, pH, temperature and osmotic pressure must be 
considered for proper formulation and delivery prior to subcutaneous injections.66 Injection 
volume is limited (< 1.5 mL)72 within the subcutaneous space due to the high concentration of 
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structural proteins and polymers used to insulate underlying musculoskeletal tissue from thermal 
and mechanical stressors.73 
 
1.6  Controlled release strategies for parenterally delivered biologics 
General objectives of a quality biotherapeutic formulation are:  protect the protein from 
degradation, increase the therapeutic half-life, increase efficacy, reduce side effects, reduce dose 
frequency, reduce dose amount, alleviate pain associated with injection and reduce the cost of 
treatment. Strategies to enhance therapeutic half-life, stability and efficacy of a protein therapeutic 
can be divided into two approaches: chemical modification and colloidal incorporation.34  
 
1.6.1 Chemical modifications  
Delivery strategies which chemically modify protein therapeutics in order to control their 
release have been generally shown to improve biologic stability and slow clearance.34 These 
strategies include PEGylation, acylation, and hyperglycosylation. Specific studies including the 
protein therapeutic, route of administration and fold increase in half-life over controls are compiled 
in Table 1. 
 
1.6.1.1 PEGylation 
 The discovery of PEGylation of protein therapeutics and the effect on increasing 
circulation half-life was a monumental advance in the modified pharmacokinetics of protein 
therapeutics.74 This advancement enabled the approval of a number of protein therapeutics which 
were initially limited by short circulating half-lives not practical for dosing regimens or initiated 
adverse immunological responses.75 PEGylation entails the covalent conjugation of polyethylene 
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glycol (PEG) to the biotherapeutic of interest. PEG addition improves stability, half-life and 
activity of many biological products. This is  due to the altering effects on molecular weight, 
physical size, solubility and the steric hindrance of enzymatic and chemical degradants.76 The 
increased water required for solvation of ethylene glycol repeating units provides a 5-10-fold 
increase in hydrodynamic radius compared to unmodified proteins of similar molecular weight 
leading to decreased renal clearance and subsequent increased systemic circulation.77 PEG 
modification of therapeutic proteins has been found to increase half-life 4.5 to 70-fold.34.  
Covalent addition of PEG functionalized with a bioconjugate reactive handle like N-
hydroxysucccinimide esters or maleimides for semi-specific residue addition may partially inhibit 
the active site of the protein, further impacting the  therapeutic effect depending on the amino acid 
target selected.34 The balance between biological activity and improved pharmacokinetics inherent 
in the use of PEG is shown in the case of PEGylated IFN -2a. PEGylated IFN -2a exhibited a a 
93% decrease in antiviral activity. The therapeutic function of IFN -2a, was observed  following 
PEG modification, but with a 70-fold increase in serum half-life.78 PEG is not biologically 
degradable and must be cleared intact by the kidneys. This is one disadvantage of utilizing PEG 
derivatives to increase sustain therapeutic half-lives. However, toxicological studies have shown 
that at the doses generally administered for PEGylated biologics a 600-fold window exist before 
toxicity has been observed in humans.79 
 
1.6.1.2 Acylation 
 Another approach to the sustained parenteral delivery of proteins is to increase their 
lipophilicity through covalent acylation with long fatty alkyl chains.80 This strategy has been 
shown in some cases to increase the affinity for serum albumin in the blood and thereby increasing 
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the circulation half-life.81 Fatty acid conjugation to human insulin led to a 24 hour duration of 
therapeutic effect for insulin detemir (Levemir) following subcutaneous injection.82 Similarly, 
derivatization of the glucagon-like peptide-1 with a range of fatty acids was shown to reduce 
dosing frequency to a once daily administration. SAR analysis of these conjugates indicated 
increases in alkyl chain length generally led to decreases in potency, but potency was generally 
unaffected by the location of substitution near the C-terminal.83 
 
1.6.1.3 Hyperglycosylation 
 Hyperglycosylation of proteins occurs through enzymatic addition of polysaccharides to 
residues through in situ chemical ligation or site-directed mutagenesis to form a glycoconjugate.84 
Similar to PEGylation in its impact on physical properties, hyperglycosylation of protein 
therapeutics extends pharmacokinetic profiles through reduction in clearance85, but also through 
modulation of receptor-facilitated cellular uptake.86 Unlike PEG, polysaccharide additions 
resulting from hyperglycosylation are known to be biologically degradable and generally non-
toxic.87 
Subcutaneous injections of various N-glycosylated IFN-2 showed up to a 25-fold increase 
in half-life compared to unmodified cytokine, but with variable in vitro antiviral and 
antiproliferative activity.88 Effect of the selected site of glycosylation on the biological activity of 
a therapeutic protein can vary widely simply by a the difference of a few amino acids in location. 
This has been shown in the enhancement of binding versus complete inhibition of an anti-dextran 




1.6.2 Colloidal modification 
Colloidal incorporation of protein therapeutics offers multiple advantages as a delivery 
platform including protection of protein from degradation, prolonged release, reduced dosing 
frequency, increased patient compliance and tailorable plasma concentration profiles.34 Aspects of 
colloidal systems and forms which are included in this analysis include the use of biodegradable 
polymers, microparticle and nanoparticle systems, lipid based nanoparticles and micelles with case 
study details compiled in Table 2. 
 
1.6.2.1 Use of biodegradable and biocompatible polymers 
 Implantable polymeric systems for the controlled release of peptide therapeutics was first 
described by Davis91 in 1972 using polyacrylamide to deliver of insulin. However, many early 
applications struggled to reduce inflammation in response to the polymeric implants. To overcome 
these negative responses while maintaining controllable release, Langer et al.92 employed the first 
biocompatible polymeric systems to sustain release of bioactive protein for up to 100 days with 
little to no inflammation. Since that time biocompatible polymers such alginate, collagen, poly 
(lactide-co-glycolide) (PLGA) and polycaprolactones (PCL) have been some of the most 
extensively studied.34 
 
1.6.2.2 Microparticles and Nanoparticles 
 Biocompatible polymers are commonly employed as colloidal systems in the form of micro 
and nano-sized particulates. These strategies generally provide high protein loading, loading 
efficiency and release in a biologically active form.93 PLGA microparticles have been extensively 
studied for a variety systems due to its well-accepted safety profile.94 PLGA-based systems have 
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been found to provide sustained delivery of encapsulated protein therapeutics from a depot 
formation for days up to months.94 The rate and extent of drug release from particles can depend 
on both manufacturing technique and the polymers selected.34, 95 A degarelix-loaded PLGA 
microparticle study screened three different fabrication techniques; spray drying, extrusion and 
double emulsion for their duration of release and biological inhibition of secreted hormone 
following a subcutaneous injection. Duration of inhibition was found to range from 14 days for 
emulsified drug, 36 days for spray-dried product and 29 days for unformulated drug.96, 97 In this 
study, the emulsion based systems were also found to be severely less potent in an in vitro 
examination suggesting destabilization of the protein and thus a likely cause for its reduced in vivo 
efficacy.  
The short in vivo half-life of IFN-2b  following i.v. infusions, which was responsible for 
frequent inconvenient and painful injections, drove researchers to develop a microparticle drug 
delivery system. The microparticle was composed of a gelatin core encapsulating the protein drug 
followed by a PLGA:Poly(ethylene glycal/butylene terephthalate) shell which when injected 
subcutaneously, sustained plasma levels of biologically active drug for 13 days compared to less 
than 12 hours when injected as a simple solution.98 
 Although considerable improvements were achieved in reducing the dose frequency, 
monthly versus every 2 days99, of Genentech’s Nutropin (Somatropin, recombinant human 
growth hormone) when formulated into a depot injection system using Alkermes ProLease 
extended release platform, commercialization was discontinued after 5 years due to the “significant 
resources required” to manufacture the product.100 Nutropin is now delivered in a multi-dose 
prefilled-syringe with daily subcutaneous injections.101 These results further support the required 
assessment on the net benefits of using fabricated microparticles for protein delivery systems 
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considering their variability in manufacturing complexity weighed against their therapeutic 
benefits.  
 Like microparticles, nanoparticles can be fabricated out of a range of materials including 
lipids and polymers, but are generally defined as particles of a diameter less than 1000 nm.102, 103 
The reduced size of nanoparticles compared to micro-sized particles has been shown to have 
effects on cellular uptake, drug release due to surface area to volume differences and injection site 
duration.104 Nanoparticles have been utilized to effectively control delivery of both small 
molecules as well as peptide and protein therapeutics.105 In one study encapsulating the protein 
therapeutic salmon calcitonin (sCT) into a mixed Eudragit:PLGA nanoparticle through a double 
emulsion technique, only modest gains (1.3-fold) in the extension of release were seen over protein 
solution controls.106 
 
1.6.2.3 Lipid vesicles 
 Lipid vesicles including solid lipid nanoparticles (SLNs) and liposomes are another 
colloidal delivery system designed to sustain the release of a myriad of drug products. SLNs are 
generally composed of a solid lipid matrix (e.g. triglycerides, fatty acids, steroids or waxes) 
stabilized by emulsifiers in an aqueous phase by high pressure homogenization.107, 108  SLNs have 
been shown to significantly extend release profiles of biologically active drug in vivo.108 These 
lipid vesicles are capable of incorporating both hydrophobic and hydrophilic proteins and peptides 
through internalization or surface adsorption been shown to significantly extend release profiles 
of biologically active drug in vivo.108 
 Liposomes are composed of a lipid bilayer surrounding an aqueous core preferentially 
formed by the natural exclusion of water by phospholipid hydrophobic lipid domains.109 Diameters 
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of liposomes can range from the 20nm to microns in size depending on the manufacturing process 
which may include high-energy sonication, extrusion or filtration.110 Known issues persist with 
the intrinsic instability of liposomes following injection leading to burst release of loaded drug.  
To combat unwanted burst release and to avoid macrophage endocytosis, some researchers have 
stabilized liposomes by encapsulation into polymeric shells or PEGylated their aqueous exposed 
polar head group.111 Yatuv et al. developed a sustained liposomal delivery system in order to 
reduce the injection frequency required for coagulation factor VIII (FVIII) replacement therapy 
for hemophilia A patients. The platform technology utilizes PEG stabilized liposomes (PEGLip) 
which can adhere to specific amino acid sequences inserted into a protein therapeutic.112 Following 
intravenous infusion, standard FVIII treatment provided a mean number of days without bleed of 
7.2 days while PEGLip FVIII provided 13.3 days of sustained biological activity.113 One downside 




Similar to liposomal drug delivery systems, micelles are colloids formed from hydrophobic 
water exclusion, but in the form of a monolayer of amphipathic surfactants surrounding a 
hydrophobic core. Micellar formulations of macromolecules have been particularly studied for 
their ability to preferentially accumulate within tumors due to the enhanced permeability and 
retention effect (EPR) brought on by compromised vasculature surrounding fast-growing 
tumors.114 Micelles and/or nanoparticles have been shown to be effective in delivering to such 
areas due to their extended circulation time which is required for adequate accumulation within 
the growing tumor.115 
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1.6.3  Hydrogels 
 Hydrogels have been traditionally defined as cross-linked polymeric networks capable of 
retaining large amounts of water without dissolving in order to maintain their three dimensional 
form.116 Since their discovery in the early 1960s117, hydrogels have been employed for a number 
of biomedical applications118 outside of drug delivery such as tissue engineering119, 120, biomedical 
coatings121, 122 and diagnostic applications.123, 124 Generally regarded as biocompatible due to their 
hydrophilicity and malleability, hydrogels have the ability to load large amounts of water-soluble 
therapeutics and therefore are well-suited for protein drugs. In addition, unlike the colloidal 
delivery systems described up to this point, hydrogels generally don’t require fabrication processes 
which could negatively affect protein stability such as exposure to organic solvents, sonication, 
extreme shear forces or temperatures. These attractive properties have led researchers to develop 
numerous designs which can enable sustained release of protein therapeutics generally through 
two broad methods: chemically or physically cross-linked polymers (Table 3).116 
 
1.6.3.1 Chemically cross-linked 
 Radical induced polymerization through UV or visible light is a commonly utilized means 
of chemical cross-linking in hydrogel systems.125 In general, the chemical reaction between 
polymers is performed in situ in the presence of a photoinitiator which is decomposed when 
exposed to light forming a free radical. When these light-induced radicals are in the vicinity of 
polymers bearing addtional polymerizable groups such a methacrylates or acrylates, a gel is 
formed.126 The ability to crosslink a gel in vivo in a minimally invasive manner is one of the major 
advantages of light induced hydrogels in addition to the fast-pace of the reaction, body temperature 
compatibility and the spatial and temporal control of initiation. Leech et. al demonstrated the in 
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vitro sustained release of the model protein bovine serum albumin (BSA) through encapsulation 
within a hyaluronic acid-glycidyl methacrylate (GMHA) and PEG-acrylate hydrogel, crosslinked 
with UV light.127, 128 Alone the GMHA-PEG acrylate hydrogel was shown to provide release over 
a 6 hour period in which 60% of the BSA loaded was released, however when the hydrogel was 
seeded with BSA loaded PLGA microspheres release was extended to several weeks. BSA in both 
systems was shown to retain its monomeric structure by GPC retention. The major drawback of 
hydrogel systems crosslinked by UV-light is the potential for chemical degradation of the protein 
therapeutic due to the effects of free radical oxidation129, however multiple reports have indicated 
preservation of activity of encapsulated enzymes following UV treatment.130, 131 
 
1.6.3.2 Physically cross-linked 
  Non-covalent physical forces which are able to crosslink hydrogel polymer networks and 
sustain the delivery of proteins include hydrophobic interactions, ionic interactions and hydrogen 
bonds.  Hydrophobic interactions are the most highly explored due to their strength and natural 
tendency to form in an aqueous environment using amphiphilic polymers. Hydrophobic and 
electrostatic interactions between polymer-modified cyclodextrin hosts, which are known for their 
binding pockets, and polymer-modified guest pairing agents have been utilized to form inclusion 
complexes which trap proteins to modify their release.132, 133 van de Manakker et al. demonstrated 
the applicability of such a supramolecular structure by complexing an 8-arm PEG, end-modified 
with -cyclodextrin or cholesterol in the presence of BSA and lysozyme. In an in vitro release 
model, sustained release of both proteins in occurred for more than nine days at which time the 




 Nanogels seek to incorporate the same functionalities and advantages of macro hydrogel 
delivery into a nano-sized vesicle able to circulate systemically for extended periods where they 
are able to overcome biological barriers due to their smaller dimensions.136 A study by Hirakura 
et al. reported the development of a nanogel protein delivery system in which the polysaccharide 
pullulan was derivatized with the hydrophobic molecule cholesteryl and mixed with model 
peptides to form a spontaneous 20-30 nm assembly. These protein/nanogel complexes were then 
loaded into an acrylate crosslinked hyaluronan hydrogel and their release monitored in vivo 
following subcutaneous implantation. Mean residence time of the model protein erythropoietin 
(EPO) increased from 39h to 146h with increasing hydrogel concentration and constant nanogel 
concentration. EPO associated alone with the nanogel had a mean residence time of 18h. Plasma 
concentrations were examined using ELISA based techniques which indicate EPO retains some 
native structure following release from the hybrid gel.137 
 
1.6.3.3.1 Mechanical properties 
The hydrophobic, electrostatic and hydrogen bond interactions which enable the self-
assembly of physically-crosslinked nanogels and their association with biopharmaceutics are 
dynamic and reversible in the nature. In contrast to chemically crosslinked hydrogels, hydrogels 
with reversible physical crosslinks can gel at rest, but when shear stress is applied upon injection 
they exhibit the properties of a low-viscosity fluid.137 These shear-thinning hydrogels, exhibit this 
behavior due to the disruption of the equilibrium governing their self-assembly upon applied shear, 
those favoring assembly (e.g. hydrophobic) and those forces that act against assembly (e.g. 
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solvation). Together these weak dynamic forces lead to a stable network upon reassembly of 
equilibrium.138, 139  
 
1.6.3.3.2 Protein release mechanisms 
The main pathways governing protein release from physically-crosslinked hydrogel 
systems are dissociation-, diffusion- and degradation-controlled release. In nanogels designed to 
associate with protein therapeutics to sustain their release, the rate of dissociation can be the rate-
limiting factor to the ultimate release of protein from the gel. 140 Diffusion-controlled release 
systems generally follow Higuchi’s kinetics in which the release rate is proportional to the square 
root of time.141 Degradation or swelling-controlled release is governed by the alteration of the 
physical properties of the gel with time due events such as gel erosion. Release of protein from 
gels due to degradation alone generally follow near zero-order kinetics.134 
 
1.7 Experimental methods to model subcutaneous release kinetics in vitro 
Reliable in vitro methods which accurately predict the in vivo performance of a 
subcutaneously administered biologic have been historically difficult. Wide variability can exist 
in the stressors and interactions a protein experiences in the early stages following injection.  
Systems such as the recently described subcutaneous injection site simulator, Scissor142, seek to 
model these events through the thorough adaptation of the physiological conditions and ECM 
components of the hypodermis hypothesized to be primary factors in the ultimate bioavailability 
of a protein. These physiological conditions include pH, ionic composition, interstitial pressure 
and temperature as well as concentrated hyaluronic acid within a semipermeable dialysis 
membrane. Initial examination of the Scissor system using four model proteins provided critical 
 30 
insight into the fate of a biopharmaceutical upon injection including excipient release, protein 
precipitation and resolubilization and the modifying effects of ECM elements. 
 
1.8 Protein stability assessment 
The release of biologically active protein from experimental drug delivery systems is 
paramount to its clinical viability.80 Evaluation of the effects of delivery systems on a protein’s 
native structure including chemical, colloidal and conformational stability provide insights which 
guide further development. A number of techniques are regularly employed to evaluate the 
structural stability of a protein drug candidate including liquid chromatography, mass 
spectrometry, Fourier transform infrared spectroscopy (FTIR), circular dichroism (CD), 
fluorescence spectroscopy and differential scanning calorimetry (DSC). When combined these 




Development of novel drug delivery systems which enable the controlled release and 
therapeutic performance of critical drugs is an area of continued focus in the research community. 
A comprehensive understanding of the determinants which govern delivery of drugs with a range 
of physical and chemical properties is required for the design and selection of an effective dosage 
form. Chemical and colloidal strategies have been effectively used to overcome the significant 
challenges to the delivery of protein therapeutics. Overall, the chemical and physical properties of 
hydrogels, coupled with their usually mild fabrication make them an attractive platform for the 
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design of a tailorable reservoir system. Further research is required to develop hydrogel systems 






















Table 1. Recent chemical modification strategies for the sustained parenteral delivery of proteins 
therapeutics. 
Broad Strategy Material Protein Route 
of 
Admin. 























PEGylation mPEG rhTSH i.m. ~1.5 Mono- cysteine 
substitution with 










only 7% of 
antiviral activity 





Asparaginase i.v. 4 86% enzymatic 















IFN-2b s.c. 25 10-fold reduction 
in in vitro 
antiviral activity. 
34, 88 
i.p.: intraperitoneal; i.v.: intraveneous; i.m.: intramuscular; s.c.: subcutaneous;  
PEG: Polyethylene glycol; PSA: polysialic acid 
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Material Protein Route 
of 
Admin. 





Microparticle PLGA Degarelix s.c. 1.25 to 
 (-2) 
Spray dried formulation 
was only formulation that 
extended inhibition over 









IFN-2b s.c. 26 S/O/W emulsion method 




rhGH s.c. 13 Nonaqueous, cryogenic 
fabrication with 








Insulin s.c. 9 O/W emulsion method. 









s.c. 1.3 Double emulsion method 
with 69-83% EE. 400-700 









rFVIII i.v. 1.8 Thin-lipid film 
hydration/extrusion. PEG 
binds to conserved 8 
amino acid sequence. 
112, 
113 
i.p.: intraperitoneal; i.v.: intraveneous; i.m.: intramuscular; s.c.: subcutaneous;  
PEG: Polyethylene glycol; PLGA: poly(lactic-co-glycolic acid) 
POPC: 1-palmitoyl-2-oleoyl-glycero-3-phosphocoholine;  











Material Protein Route 
of 
Admin. 

























































i.p.: intraperitoneal; i.v.: intraveneous; i.m.: intramuscular; s.c.: subcutaneous;  
CC: chemically-crosslinked; PC: physically-crosslinked 
PEG: Polyethylene glycol; PLGA: poly(lactic-co-glycolic acid) 
GMHA: glycidyl methacrylate hyaluronic acid 
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2.1 Introduction 
 New pharmaceutical drugs may be small molecules, peptides or proteins of 10’s to 
100kDa’s in size. There is no single universal delivery system able to encapsulate and sustain the 
delivery of all molecules, which cover a wide spectrum of biophysical properties. Amphiphilic 
polymer derivatives composed of  hydrophilic and hydrophobic domains are extensively used to 
encapsulate and control delivery of small molecule therapeutics following self-assembly into 
micelle-like structures, both currently and historically.1 These materials are also compatible with 
large molecules such as D--Tocopherol modified poly ethylene glycol 1000 (PEG1000)  succinate 
(TPGS), was first synthesized by the Eastman Kodak Company in the 1950s as a water soluble 
vitamin E supplement suitable for oral administration. TPGS is now generally recognized as safe 
(GRAS) and approved for use as a pharmaceutical emulsifier, solubilizer, detergent and 
permeation enhancer.2, 3 TPGS has been shown to increase the solubility of multiple poorly soluble 
drugs through incorporation within its amphiphilic structure in which the lipophilic tocopherol 
alkyl tail forms the core of the drug encapsulating micelle while the hydrophilic PEG forms the 
aqueous exposed shell.4-6 In addition to enhancing drug solubility, TPGS has also been shown to 
effectively control the release kinetics of small molecule therapeutics7 and biologics8 following 
administration. In a similar amphiphilic platform to TPGS, the polysaccharide dextran was 
hydrophobically modified with -tocopherol succinate to enable the formation of a self-
assembling micelle, which effectively encapsulated and sustained the in vitro release of the 
chemotherapeutic doxorubicin for 96 h.9 
  Several carrier systems, including  tocopherol-modified dextran, are currently under 
investigation to determine the plausibility of employing  polymers which are biologically 
compatible, biodegradable, with low immunogenicity and toxicity while also providing attractive 
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biological and physico-chemical functionality.10 Polysaccharides such as dextran11, chitosan12 and 
hyaluronic acid13 have been extensively researched in this regard due to their hydrophilicity, large 
variety in chemical composition and biological functionality, and for their ease of production.14 
Hyaluronic acid has been shown to be a particularly attractive drug carrier due to the following 
characteristics: its tunability15, both in physical13 and in chemical character16, its CD44 receptor 
affinity, which is frequently over expressed on tumor surfaces,17 as well as its potential for 
intralymphatic delivery following subcutaneous injections.18  
 Hyaluronic acid or hyaluronan (HA) is a linear polysaccharide is ubiquitous within human 
physiology, particularly as a major component of the extra cellular matrix (ECM).19 The structure 
of HA consists of alternating units of the repeating -1,4- D-glucuronic acid--1,3-N-actyl-D-
glucosamine disaccharide. HA is an anionic, non-sulfated glycosaminoglycan with endogenous 
molecular weight from 100 kDa to 8 MDa. HA is readily degraded by a family of endogenous 
enzymes named hyaluronidase, which are expressed in nearly all human tissues.13, 20, 21   
Hydrophobic modification of  HA through covalent addition of a variety of hydrophobic 
substituents has been shown to create self-assembled particles.22, 23 These particles are capable of 
non-covalently  associating with a wide-range of pharmaceutically relevant small molecule 
payloads including fluorescent dyes,24, 25 chemotherapeutics26, 27 and corticosteroids.28 In these 
cases, the resulting amphiphilic HA derivatives provided extended drug release kinetics without 
negatively impacting the desired therapeutic or diagnostic effect. Recently our lab showed that a 
tocopherol-modified HA conjugate (HAtoco) complexed with a potent toll-like receptor 7/8 
agonist sustained local anti-tumor immunomodulatory effects when injected intratumorally.29 
Upon injection, a nano-suspension depot was formed, effectively suppressing tumor growth in 
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murine synergistic tumors and spontaneous canine cancers with no adverse systemic 
immunological responses.  
The objective of this study is to explore the application of the HAtoco conjugate which 
includes optimization of its physical attributes, applicability to the delivery of protein therapeutics, 
characterization of its in vivo release kinetics and the assessment of  the conjugate’s physical, 
chemical and enzymatic stability. 
 
2.2 Materials and Methods 
2.2.1 Materials 
Sodium hyaluronate (HA) was obtained from Lifecore Biomedical (Chaska, MN). 
SnakeSkin Dialysis Tubing and N-hydroxysulfosuccinimide (Sulfo-NHS) were obtained from 
Thermo Fisher Scientific (Waltham, MA). Float-A-Lyzer G2 Dialysis Devices were purchased 
from Spectrum Labs (Waltham, MA). Cyanine7-amine (Cy7-Amine) was purchased from 
Lumiprobe (Hunt Valley, MD). Chemical reagents including, Stains-all, hyaluronidase from 
bovine testes (+)--tocopherol, 1-ethyl-3-(e-dimethylaminopropyl)carbodiimide hydrochloride 
(EDC-HCl), N,N’-dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine (DMAP), N-(tert-
butoxycarbonyl) glycine (Boc-Gly-OH), trifluoroacetic acid (TFA), tetrabutylammonium 
hydroxide (TBA-OH), and 1-hydroxybenzotriazole hydrate (HOBT-H2O) were purchased from 
Sigma Aldrich (St. Louis, MO). TAE buffer (40X) molecular biology grade was purchased from 
Promega (Madison, WI).  Solvents for flash chromatography, HPLC grade solvents, agarose, and 




2.2.2 Synthesis of hyaluronan – vitamin E conjugate (HAtoco) 
Hyaluronan – tocopherol conjugates were synthesized using a glycine-modified 
tocopherol.29 (+)--Tocopherol (Vitamin E) was coupled to a Boc-protected glycine through 
DCC/DMAP mediated esterification in anhydrous CH2Cl2 overnight. The reaction mixture then 
was cooled to -20°C and filtered. The filtrate was purified by silica gel flash chromatography using 
a hexane-ethyl acetate gradient and dried in vacuo. The resulting product oil was treated with 
12.5% (v/v) TFA in CH2Cl2 for 0.5 h at 0°C and an additional 1 h at 25°C to remove Boc protecting 
groups, and subsequently dried in vacuo to remove solvent and TFA. The gray solid product was 
purified by silica gel flash chromatography using a hexane-ethyl acetate gradient with elution at 
5% ethyl acetate and again dried to yield a white solid product 1. Sodium hyaluronate (6.7, 33, 
100 or 250 kDa) were fully dissolved at 20 mg/ml in deionized water, followed by addition of 
Dowex AG 50W-X8 resin (10-fold excess to HA by mass) and stirred gently overnight at 20°C. 
The resin was removed by filtration and filtrate titrated with TBA-OH to pH 8-9, yielding a slightly 
pink solution. The HA-TBA solution was subsequently frozen and lyophilized to yield a pink-
yellow cake 2. HA-TBA was then dissolved in DMF (16.67 mg/ml, 26.85mM on a disaccharide 
basis) and subsequently added to a mixture of 1 (amount reacted ranged from 0.268-1.34mM 
corresponding to a 5-25% disaccharide substitution), EDC-HCl (1.5 molar equivalents to 1) and 
HOBT-H2O (2.5 molar equivalents to 1) in DMF. The reaction mixture was stirred at 20°C 
overnight. Product crude was dialyzed (10 kDa MWCO for  >6.7kDa HA or 3.5kDa MWCO for 
<6.7kDa HA) against 50% ethanol (v/v) for 12 h, 150 mM sodium chloride for 12 h and water 
with three changes over 72 h. The dialyzed HA-tocopherol (HAtoco) product was lyophilized to 
yield a white fibrous cake 3 (Scheme 1). Tocopherol substitution on a disaccharide molar basis 
was calculated by 1H NMR acquired on a 400 MHz Bruker AV spectrometer equipped with a X-
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channel broadband observe probe. Peak area ratios between the N-acetyl peak of HA (-CH3, 2 
ppm) and methyl groups of the tocopherol chain (12H, 0.8 ppm) were used to calculate the degree 
of substitution (Equation 1). General naming of HA-tocopherol analogs are as follows: “MW” 
HAtoco “tocopherol substitution as a percent of conjugated disaccharide units”. 
 
(1)   % 𝐷𝑒𝑔𝑟𝑒𝑒 𝑜𝑓 𝑆𝑢𝑏𝑠𝑡𝑖𝑡𝑖𝑜𝑛
= (
(𝑇𝑜𝑐𝑜𝑝ℎ𝑒𝑟𝑜𝑙 𝑀𝑒𝑡ℎ𝑦𝑙 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎, 0.8 𝑝𝑝𝑚) 12 𝑝𝑟𝑜𝑡𝑜𝑛𝑠⁄
(𝐻𝐴, 𝑁 − 𝑎𝑐𝑒𝑡𝑦𝑙 𝑃𝑒𝑎𝑘 𝐴𝑟𝑒𝑎, 2 𝑝𝑝𝑚) 3 𝑝𝑟𝑜𝑡𝑜𝑛𝑠⁄







































































































2.2.3 Assessment of protein binding capacity of HAtoco MW and substitution 
variants by intrinsic tryptophan fluorescence  
 The protein binding capacity of various hyaluronan-tocopherol analogs was assessed using 
the model-protein bovine serum albumin (BSA). BSA steady-state intrinsic tryptophan 
fluorescence spectra was acquired using a fluorescence plate reader manufactured by Fluorescence 
Innovations Inc. (Minneapolis, MN). Excitation wavelength was set at 295 nm coupled with a 310 
nm long-pass dichroic mirror. Emission spectra were acquired from 300 – 400 nm with integration 
time of 1000 ms. Spectra were acquired at 25°C. BSA in PBS at 0.1 mg/ml was used to dissolve 
lyophilized HAtoco derivatives or 33 kDa HA at 7.9, 79, 790 and 7900 M on a disaccharide basis 
with MW adjusted based on tocopherol substitution (Equation 2-6) and allowed to mix overnight 
at 20°C, protected from light. All samples were analyzed on a 384-well plate (N=6). Spectra 
contributions from HAtoco, HA or buffer were subtracted from raw data and processed using 
Microsoft Excel to derive the spectral moment (Equation 7-9) as described by Wei et al.30,  and 
plotted against an average disaccharide molecular weight concentration. 




(3)  𝐵 =  𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑛𝑜𝑛 − 𝑠𝑢𝑏𝑠𝑖𝑡𝑖𝑡𝑢𝑡𝑒𝑑 𝑑𝑖𝑠𝑎𝑐𝑐ℎ𝑎𝑟𝑖𝑑𝑒 𝑀𝑊
=  𝐴 ∗ (1 −  % 𝑇𝑜𝑐𝑜𝑝ℎ𝑒𝑟𝑜𝑙 𝑠𝑢𝑏𝑠𝑡𝑖𝑡𝑖𝑜𝑛) ∗ (𝑛𝑜𝑛 − 𝑠𝑢𝑏𝑠𝑡𝑖𝑡𝑢𝑡𝑒𝑑 𝑑𝑖𝑠𝑎𝑐𝑐ℎ𝑎𝑟𝑖𝑑𝑒 𝑀𝑊)   
(4)  𝐶 =  𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑡𝑜𝑐𝑜𝑝ℎ𝑒𝑟𝑜𝑙 𝑠𝑢𝑏𝑠𝑖𝑡𝑖𝑡𝑢𝑡𝑒𝑑 𝑑𝑖𝑠𝑎𝑐𝑐ℎ𝑎𝑟𝑖𝑑𝑒 𝑀𝑊     
=  𝐴 ∗ (% 𝑇𝑜𝑐𝑜𝑝ℎ𝑒𝑟𝑜𝑙 𝑠𝑢𝑏𝑠𝑡𝑖𝑡𝑖𝑜𝑛) ∗ (𝑡𝑜𝑐𝑜𝑝ℎ𝑒𝑟𝑜𝑙 𝑠𝑢𝑏𝑠𝑡𝑖𝑡𝑢𝑡𝑒𝑑 𝑑𝑖𝑠𝑎𝑐𝑐ℎ𝑎𝑟𝑖𝑑𝑒 𝑀𝑊)   
(5)  𝐷 =  𝐶𝑢𝑚𝑢𝑙𝑎𝑡𝑖𝑣𝑒 𝑚𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑝𝑜𝑙𝑦𝑚𝑒𝑟 𝑀𝑊 = 𝐵 + 𝐶   
(6)  𝐴𝑣𝑒𝑟𝑎𝑔𝑒 𝐷𝑖𝑠𝑎𝑐𝑐ℎ𝑎𝑟𝑖𝑑𝑒 𝑀𝑊 𝑜𝑓 𝑀𝑜𝑑𝑖𝑓𝑖𝑒𝑑 𝑃𝑜𝑙𝑦𝑚𝑒𝑟 =
𝐷
𝐴
   
(7)  𝐼𝑛𝑡𝑒𝑛𝑠𝑖𝑡𝑦 =  ∫ 𝐼(𝑥)𝑑𝑥 
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(9)  𝐼(𝑥) = 𝑓𝑙𝑢𝑜𝑟𝑒𝑠𝑐𝑒𝑛𝑡 𝑠𝑖𝑔𝑛𝑎𝑙 𝑎𝑡 𝑤𝑎𝑣𝑒𝑙𝑒𝑛𝑔𝑡ℎ (𝑥) 
 
2.2.4 In vitro release of model proteins formulated with HAtoco 
 Model proteins BSA, lysozyme and RNAase were dissolved in deionized PBS, pH 7.4 to 
10 mg/ml and subsequently added to an equal mass of lyophilized 33 kDa HAtoco10 or 33 kDa 
HA. The protein/HAtoco solution was mixed overnight at 20°C covered from light. Float-A-Lyzer 
dialysis cassettes (300 kDa MWCO) were filled with 0.8 ml of 1% (w/v) 622 kDa sodium 
hyaluronate (HMW HA) in PBS, pH 7.4 with 0.05% (w/v) NaN3 as an anti-microbial agent. 
Protein/HAtoco mixtures (0.2 ml) were pipetted into the HMW HA solution within the dialysis 
cassette and dialyzed against 30 ml of PBS, pH 7.4, 0.05% (w/v) NaN3, in a 50 ml conical 
centrifuge tube at 37°C while stirring. All release experiments were performed in triplicate. At 
predetermined intervals, the entire dialysate volume was replaced with fresh buffer and prior 
dialysate frozen at -80°C for future analysis. Percent protein released was determined by HPLC 
peak area against a standard curve. All chromatography was performed on a Shimadzu LC-2010C 
HT (Kyoto, Japan) with in-line UV detection (280 nm) using an Phenomenex Aeries 3.6 m 
Widepore XB-C18 column (250 x 4.5 mm) at 50°C. Gradient mobile phases were A: 9:1, 
H2O:Acetonitrile, 0.05% (v/v) TFA and B: 1:9, H2O:Acetonitrile, 0.05% (v/v) TFA with elution 
20-100% B over 6 min at a flow rate of 1.0 ml/min. Formulas for determining percent drug released 





) ∗ 𝐷𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙)




%𝐶𝐷𝑅𝑡 = %𝐷𝑅𝑡 + 𝐶𝐷𝑅𝑡−1 
 
where %DRt = percentage of drug released at time (t); %CDRt-1 = cumulative drug released at time 
point prior to (t); %CDRt = cumulative drug released at time (t). Release profiles were fit using a 
one phase decay nonlinear regression in Prism 6 (Graphpad Software, San Diego, CA).  
 
2.2.5 Viscosity of HAtoco 
 The viscosity of 33kDa HAtoco10 was measured using a Brookfield DV-III Programmable 
Rheometer (Middleboro, MA) with a cone spindle and Thermo NESLAB RTE 740 circulating 
bath (Thermo Scientific) against Brookfield viscosity standards (4.9, 9.5, 49 cP) at 25°C. 33kDa 
HAtoco10 was dissolved to 10 mg/ml (23.26 mM discaccharide basis) and HA standards of 6.4, 
33, 100, 200 and 622 kDa were dissolved to 9.33 mg/ml (23.26 mM discaccharide basis). 
Measurements were made in triplicate with individual sample torques adjusted as closely as 
possible to 60%. 33kDa HAtoco10 apparent molecular weight was determined through 
interpolation of a non-linear regression (one-phase decay) of the known molecular weight HA 
standards using Graphpad Prism 6. 
 
2.2.6 HAtoco Solution Turbidity 
 Solution turbidity was analyzed using a Hach 2100N Turbidimeter (Loveland, CO) 
calibrated using Stablcal Turbidity Standards (7500 – 0.1 NTU). Measurements were made using 
33kDa HAtoco10 , 200 kDa and 33 kDa HA at 10 mg/ml in PBS, pH 7.4. Measurements were 
made in single replicates due to volume requirements.  
 62 
2.2.7 Characterization of HAtoco by Gel Permeation Chromatography and 
Agarose gel electrophoresis 
 Gel permeation chromatography was performed on a Shodex HQ-806M column with 5mM 
ammonium acetate, pH 5, at a flow rate of 0.8 ml/min within a 40°C oven using a Shimadzu LC-
2010C HT. Elution profiles were monitored using an in-line UV/Vis detector at 214 nm and in-
line fluorescence detector (295 Ex./330 Em.) using a Waters 2475 Multi  Fluorescence Detector 
(Milford, MA). Samples were dissolved initially at 1.5 mg/ml in PBS overnight at 25°C without 
shaking and then diluted five-fold in mobile phase buffer prior to injection (80l). 
 Agarose gel electrophoresis was performed based on the protocol of Cowan et al.31 on a 
Fisher Scientific mini-horizontal electrophoresis unit (Hampton, NH). Agarose (500 mg) was first 
suspended in 50 ml (1% (w/v)) 1X TAE buffer (40mM Tris-acetate, 1 mM EDTA, pH 8.2-8.4). 
The suspension was heated in a 1100 W microwave for 50 s with stirring ever 10 s until light 
boiling occurred. The solution was then poured evenly onto a 7 x 10 mm tray with a 10-well comb 
and allowed to solidify at room temperature for 30 min. Once solidified, gel was oriented to run 
towards the anode terminal and submerged in 300 ml of 1X TAE buffer. 33kDa HAtoco 10 and 
HA standards (6.4, 33, 60, 100, 200, 323, 622 and 2000 kDa) were dissolved to 0.5 mg/ml in PBS, 
15 l removed and mixed with 30 l of water and 9 l of loading buffer (0.02% (w/v) bromophenol 
blue, 2M sucrose, 1X TAE buffer). An 18 l aliquot of each sample (2.5 g) was loaded into each 
well and electrophoresis carried out at ambient temperature at a constant voltage of 20V for 30 
min and 40V for 2 h. Following the run, gels were submerged in a staining solution of 0.005% 
(w/v) Stains-all, 50% (v/v) ethanol and incubated at ambient temperature protected from light for 
12 h. Gels were destained by submerging in 10% (v/v) ethanol covered from light for one day with 
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at least one bath change. Final destaining was performed by exposing the gel to laboratory room 
fluorescent lighting for 10 min before imaging. 
  
2.2.8 HAtoco Particle Characterization by Dynamic Light Scattering and Micro 
Flow Imaging 
 The 33kDa HAtoco10 particles were analyzed using a Brookhaven ZetaPALS 
(Brookhaven Instrument Corporation, Holtsville, NY) and a MFI 5000 Series (ProteinSimple) 
instruments. Samples were dissolved to 10, 5, 2.5, 1.25 and 0.625 mg/ml for the DLS studies and 
1 mg/ml for the MFI experiment in PBS, pH 7.4, overnight at 25°C. Dynamic light scattering was 
performed using a 653 nm laser placed at 90 degrees with samples measured in five acquisitions 
at an acquisition time of 30 s each. The viscosities of samples were set at 16.4 cP for 10mg/ml 
HAtoco based on previous measurements (Sec. 2.2.5) and iteratively decreased with concentration 
to the viscosity of PBS (0.89 cP) based on published rheological studies on the correlation of 
concentration and hyaluronan viscosity.32, 33 Inputted viscosity parameters for each concentration 
are reported in Figure 2.13. Autocorrelation functions were fit using a NNLS (non-negative least 
squares) algorithm within the instrument software and reported as number and intensity average 
diameter  and distributions. Polydispersity of the distribution was measured by cumulants analysis 
of the autocorrelation function within the instrument software. MFI measurements were made in 






2.2.9 Thermal Dependence of HAtoco Static Light Scattering 
 Static light scattering of HAtoco was collected using a steady-state fluorometer (Photon 
Technology International/Horiba, Kyoto, Japan). 33kDa HAtoco10 or 33kDa HA was dissolved 
to 10 mg/ml in PBS, pH 7.4 overnight at room temperature, protected from light. Samples were 
measured in quartz cuvettes excited at 405 nm and emission detected at the same wavelength at 
180°. Measurements were made from 10 to 90°C in 2.5°C increments with an equilibration time 
of 2 min.  
 
2.2.10 Synthesis and Characterization of HAtoco and HA Cy7 Conjugates 
 Fluorescently labeled HA or HAtoco was synthesized (Scheme 2) by first dissolving 5 mg 
(0.0124 mmol disaccharide) of 33 kDa HA or 33 kDa HAtoco (0.0116 mmol disaccharide) to 10 
mg/ml in 0.1 M MES, pH 4.25 overnight at room temperature. Next, 23.7 mg (0.124 mmol) EDC-
HCl and 26.9 mg Sulfo-NHS (0.124 mmol) was added to the HA solution sequentially and stirred 
for 15 min at room temperature. Cy7-Amine (0.25 mg, 0.35 mol, 0.03 molar equivalents to 
HA/HAtoco disaccharide) pre-dissolved to 2 mg/ml in DMSO was diluted 4-fold in PBS, pH 7.4, 
(0.5 ml final volume) and added to stirring HA/EDC/Sulfo-NHS solution. The reaction proceeded 
for 4 h at ambient temperature protected from light. Unconjugated dye and coupling reagents were 
removed by exhaustive dialysis using a 10 kDa MWCO membrane against a 2 L bath of PBS, pH 
7.4 for 12 h, repeated three times and stored at 4°C until further testing. 
   
2.2.11 In vivo release following subcutaneous injection 
All animal studies were approved by the University of Kansas Institutional Animal Care 
and Use Committee. Female BALB/c mice (16 – 20 g) were purchased from Charles River. Hair 
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in the hind limbs was removed prior to treatment and imaging to reduce autofluorescence using 
depilatory cream. Assuming 100% mass recovery, purified HA-Cy7 (7.14 mg/ml) and HAtoco-
Cy7 (10 mg/ml) samples were diluted 4-fold and 2-fold respectively with 10 mg/ml matching non-
fluorescent samples to a final molar concentration of 23.26 mM on a disaccharide basis. Initial 
sample fluorescent intensities were visually assessed as comparable. Mice (3 per group) were 
anesthetized with isoflurane (3%) and injected subcutaneously with 10 l of HAtoco-Cy7 or HA-
Cy7 in the center of the hind footpad. Whole body fluorescent images were acquired at 
predetermined timepoints using a CRi Maestro In Vivo Imaging System (Cambridge Research & 
Instrumentation, Inc., Woburn, MA) equipped with a 671 – 705 nm excitation bandpass filter and 
an 800 nm long pass emission filter. All images acquired at a constant exposure of 2000 ms at 810 
nm and equally scaled using the instrument software. Quantification of fluorescent intensity 
remaining at the injection site was performed by exporting images to ImageJ and adjusting 
threshold to a pixel intensity greater than 10 for HA-Cy7 images and greater than 200 for HAtoco-
Cy7 in an effort to compensate for differences in sample intensities and to adequately distinguish 
from autofluorescence. Integrated density (mean intensity*area) of the remaining fluorescent 
signal was measured from the area of the entire foot to the ankle. Signal for intensities for both 
samples were normalized for comparison, and an elimination phase fit was performed using a non-
linear, one-phase decay model in Graphpad Prism 6. 
 
2.2.12 Evaluation of HAtoco conjugate chemical stability  by High Performance 
Liquid Chromatography 
Chemical stability of the glycine-ester linkage between hyaluronan and tocopherol at 
elevated temperatures was assessed by monitoring the free tocopherol within the HAtoco solution 
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over time through an adapted serum extraction procedure prior to RP-HPLC quantification.34 
33kDa HAtoco10 was first dissolved to 10 mg/ml in PBS, pH 6 and placed at 37°C in sealed 
containers for 0h, 1h, 4h, 8h, 24h, 48h and 8 days. Samples were removed at designated time-
points and frozen at -20°C until further testing. The general extraction work flow begins with 300 
l of test sample (10mg/ml HAtoco or buffer control) to which 600 l of absolute ethanol is added 
and the mixture vortexed for 30 s. Next, 450 l of hexane is added to the mixture and vortexed 
again for 30 s. Immiscible layers are allowed to separate (~30 s) and 300 l of the organic (top) 
layer carefully removed without disruption of the aqueous layer. Sample is then dried on a rotary 
evaporator at 170 mbar, 35°C and placed under high vacuum (<4 mbar) for 1 h at room 
temperature. Dried sample is then dissolved in 200 l of absolute ethanol and tested for tocopherol 
content by RP-HPLC. Extraction recovery was examined by suspending a known amount of 
tocopherol oil in a fresh solution of 10mg/ml HAtoco to a concentration of 500 g/ml (N=5) and 
proceeding with extraction of the entire volume as described above.  RP-HPLC analysis was 
performed using a Shimadzu LC-2010C HT with in-line UV detection (280 nm). Chromatography 
was performed on a ZORBAX Eclipse XDB 80Å C8 column (50 x 2.1 mm, 5m) at 35°C. 
Gradient mobile phases were A: H2O and B: Acetonitrile with elution 10% B over 5 min, ramp to 
100% B over 10 min, hold for 3 min and ramp to initial conditions over 3 min. Mobile phase was 
set at a flow rate of 1.0 ml/min. Tocopherol concentration was determined through peak area 






2.2.13 Hyaluronidase Degradation of HAtoco 
 The 33kDa HAtoco10 and 200 kDa HA were dissolved in PBS, pH 6 to 10.526 mg/ml 
overnight at 25°C without shaking. Hyaluronidase from bovine testes (HAdase) was dissolved 
separately in PBS, pH 6 to 1 mg/ml overnight at 25°C protected from light. Samples were heated 
to 37°C in an oil bath and mixed to give a final concentration of 10 mg/ml HAtoco or 200 kDa HA 
with or without 50 g/ml HAdase. Mixtures were sampled at 24h, 48h and 8 days and stored at -
80°C until further analysis. All samples were thawed to room temperature and analyzed by agarose 
electrophoresis as described previously with the modification that 10 g samples were loaded for 
HAtoco for heightened signal, and the electrophoresis run conditions were extended to a constant 




2.3.1 Synthesis of hyaluronan – tocopherol conjugates 
 Hyaluronic acid was successfully reacted with glycine-modified -tocopherol through 
EDC/HOBt mediated amidation of the D-glucoronic acid carboxylate (Scheme 1) with unreacted 
tocopherol removed by exhaustive dialysis. Tocopherol substitution onto the backbone of HA 
was quantified by 1H NMR using the peak area ratio of the HA N-acetyl protons (1.9 ppm) and 
the tocopherol side chain methyl protons (0.8 ppm) (Figure 2.1). HAtoco conjugates of varying 
degree of substitution (5-25%, Figure 2.2, 2.3) and molecular weight (6.7-250 kDa, Figure 2.4) 
were synthesized with actual substitution and reaction efficiency tabulated in Table 1. 
 Slight increases in the reaction efficiency of 33kDa HAtoco were observed with 
increasing degree of tocopherol substitution (63-83%), but noticeable differences were seen in 
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the hydration rate and extent with higher substitutions. Poor dissolution was observed for 
conjugates with higher than 10 mol% substitution, which is exemplified in the decreasing 
intensity of the 1H NMR signal. In addition, peak broadening with higher substitution was 
observed, likely indicative of increasing polydispersity. Similarly, conjugates of varying 
molecular weight with a constant substitution of 10 mol% had reaction efficiencies ranging from 
(71-90%), but with no clear correlation to molecular weight. HAtoco conjugates of molecular 
weight greater than 33kDa struggled to dissolved, similar to conjugates with >10mol% 
substitutions. 1H NMR signal intensity reductions and peak broadening are again observable with 
increasing molecular weight. Overall, HA base-polymer molecular weight no greater than 33kDa 
and tocopherol substitution no greater than 10mol% were observed to exemplify dissolution 

















Figure 2.1: 1H NMR spectra of 33 kDa HA (above) and 33 kDa HA tocopherol, 10 mol% subst.  
(below) with contributions from N-acetyl peak of HA (a, -CH3, 2.0 ppm) and methyl group of 














Figure 2.2: Stacked 1H NMR spectra of 33 kDa HA with tocopherol substitutions from 5-25 mol% 
stoichiometry. Signal intensity of N-acetyl protons (2.0 ppm) normalized for substitution 



















Figure 2.3: Overlayed 1H NMR spectra of 33 kDa HA with tocopherol substitution from 5-25 
mol% stoichiometry. Signal intensity of N-acetyl protons (2.0 ppm) normalized for substitution 


































Figure 2.4: Stacked 1H NMR spectra of 6.7, 33, 100 and 250 kDa HA with tocopherol substitution 






























Table 1: Compiled degree of substitution analysis for all HAtoco variants by 1H NMR peak area 
analysis (Equation 1) of hyaluronan N-acetyl protons (3H, 2.0 ppm) and methyl tocopherol chain 








Actual (mol%) Efficiency (%)
33 5 3.1 62.4
33 10 7.1 71.2
33 15 12.8 85.6
33 20 17.1 85.7
33 25 20.6 82.5
6.7 10 8.4 83.8
33 10 7.1 71.2
100 10 7.5 75.3
250 10 9.1 90.9
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2.3.2 Assessment of protein binding capacity of HAtoco MW and substitution 
variants by intrinsic tryptophan fluorescence 
 In a continuation of previous studies29 where HAtoco was shown to complex with a 
hydrophobic small molecule TLR agonist in a depot-like manner, HAtoco derivatives were mixed 
with a model protein (BSA) in increasing concentrations and intrinsic tryptophan fluorescence 
spectra examined for alterations (Figure 2.5). Blue-shifts in the emission peak of BSA when mixed 
with increasing amounts of all HAtoco derivatives were observed in addition to clear quenching 
of overall signal intensity suggesting substantial increases in the apolarity of the tryptophan local 
environment likely through interaction with the tocopherol moieties. Emission peak moment also 
known as the mean spectral center of mass (MSM) was plotted against HAtoco disaccharide 
concentration to assess affinity differences between HAtoco variants and BSA (Figure 2.6). No 
clear differences were observed between different tocopherol substitution or molecular weight HA 
derivatives. 
 
2.3.3 In vitro release of model proteins formulated with HAtoco 
 The potential of HAtoco as a protein binding complex was further explored through an in 
vitro release assay intended to model the release of protein following subcutaneous injection. Due 
to the poor dissolution characteristics observed with high molecular weight (>33kDa) and high 
tocopherol substitution (>10mol%) conjugates coupled with no clear differences observed in 
protein binding by fluorescent moment shifts, 33kDa HA with a 10mol% substitution was selected 
as the lead conjugate candidate for further characterization.  
Model proteins BSA, RNase and lysozyme were mixed with 1% (w/v) 33kDa HAtoco10 
in a 1:1 (m/m) ratio and injected within a semi-permeable dialysis bag containing high molecular 
 75 
weight hyaluronan. Release dialysate was sampled at varying intervals, protein concentration 
quantified by RP-HPLC and cumulative protein released  plotted as a percentage of initial protein 
loaded (Figure 2.7). Release profiles were fit using a non-linear regression to generally assess 
release half-life between protein formulated in 33kDa HAtoco10 versus unmodified 33kDa HA. 
All HAtoco formulated model proteins were found to release with about a 2-fold longer half-life 
when compared to unmodified HA suggesting HAtoco has the potential to associate with a broader 
range of protein therapeutics. 
 
2.3.4 Viscosity Determination of HAtoco 
 Absolute viscosity of 33kDa HAtoco10 and unmodified HA standards was measured using 
a temperature-controlled rheometer validated with standards of known viscosity. HAtoco at 1% 
(w/v) was found to have a viscosity of 16.4  0.1 cP at a shear rate of 86.25 sec-1.  HAtoco apparent 
molecular weight was determined by interpolation of the non-liner fit of unmodified HA molecular 
weight versus viscosity (Figure 2.8). 33kDa HAtoco10 had a viscosity equal to unmodified 
187kDa HA at the same molar concentration indicating significant addition of viscosity occurs 














Figure 2.5: BSA (0.1 mg/ml) intrinsic tryptophan fluorescence with increasing 33kDa HAtoco10 









































Figure 2.6: BSA (0.1 mg/ml) intrinsic tryptophan fluorescence moment versus HAtoco variant 
concentration (7.9M to 7900M disaccharide basis), data points represent mean  SD (N=4). 
Data fit using a four-parameter logistic non-linear regression with Graphpad Prism 6. 33kDa 
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BSA Trp Emission Moment vs. HAtoco, % Tocopherol














Figure 2.7: In vitro release profiles of model protein RNase (left), Lysozyme (center) and BSA 
(right) formulated with 33kDa HAtoco10 or 33kDa HA. Release profiles were fit with a one-phase 
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Figure 2.8: Non-linear regression of viscosity vs. molecular weight of HA standards. Red dotted 
line indicates regression 95% confidence interval. Black dotted line indicates value obtained for 



























2.3.5 HAtoco solution turbidity 
 Visual characterization of the solid and solution states of 33kDa HAtoco10 versus 
unmodified HA are seen in Figure 2.8. Under the current processing conditions, following dialysis 
purification, HAtoco is freeze dried into a fibrous cake for extended storage stability. In contrast, 
polydisperse sodium hyaluronan reagents are purchased as a dried powder (Figure 2.8, top). When 
dissolved in PBS to 1% (w/v), 33kDa HAtoco10 presents as a turbid, but homogenous solution 
while hyaluronan of equal base polymer molecular weight (33kDa) and viscosity (200kDa) 
presents as a clear solution (Figure 2.8, bottom). Turbidity differences were quantified against 
formazin standards of specified turbidity and 1% (w/v) 33kDa HAtoco10 was found to have a 
turbidity of 102 NTU (nephelometric turbidity units) while all HA standards and buffer were found 
to have a turbidity of less than 1.3 NTU. These results suggest HAtoco develops into a self-
associating particle when dissolved in aqueous buffer. 
 
2.3.6 Characterization of HAtoco by Gel Permeation Chromatography 
 Assembly of the HAtoco particle complex and its effective size in solution was first 
assessed by gel permeation chromatography using a Shodex 806-M HQ column equilibrated with 
5 mM ammonium acetate, pH 5 mobile phase. 33kDa HAtoco10 and unmodified polydisperse HA 
standards were prepared at 1.5 mg/ml and diluted 5-fold with mobile phase prior to injection. 
Chromatography was monitored by UV-absorption at 214 nm (Figure 2.10, top). To assess column 
performance, retention volumes of HA standards were compared to pullulan polysaccharide 
standards run under similar aqueous conditions defined in the manufacturer’s certificate of analysis 
(Figure 2.10, bottom). The upper limit of resolution was found to be 100kDa based on minimal 
change in peak retention at high molecular weights. Interestingly, 33kDa HAtoco 10 had a similar 
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retention to unmodified 33kDa HA, which was unexpected based on the visual turbid particulate 
nature of the solution. To further investigate this unexpected result, in-line fluorescence detection 
was added with excitation and emission set to 295 nm and 330 nm respectively based on observed 
fluorescence from the conjugate alone during previously described protein binding assays. No 
fluorescent signal was detected throughout the entire HAtoco chromatogram. When the column 
was removed from the flow path and sample injection repeated, an immediately eluting sharp peak 
with increased UV (214nm) peak area and substantial fluorescent intensity was observed (Figure 
2.11). These results indicate that 33kDa HAtoco10 forms a large enough effective size where it is 
unable to pass through the entrance frit of an analytical gel permeation column and that it contains 

















Figure 2.9: (Top) Equal dry mass (10 mg) 33kDa HAtoco10, 33kDa HA and 200kDa HA. 
(Bottom) 33kDa HAtoco10 (10 mg/ml) visual and measured turbidity compared to 33kDa HA, 





















































Figure 2.10: (above) Gel permeation chromatograph of 33kDa HAtoco10 and HA molecular 
weight standards (323, 200, 100, 60, 33 and 6.4 kDa) run on a Shodex 806-M HQ monitored by 
UV-absorption at 214 nm. (below) Peak elution volume versus HA molecular weight standards 
compared to column certificate of analysis pullulan polysaccharide molecular weight versus 
elution correlation. 
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Figure 2.11: (a) Gel permeation chromatograph of 33kDa HAtoco10 monitored by UV-absorption 
at 214 nm with and without a Shodex 806-M HQ column (left) zoomed and (right) full scale. (b) 
Gel permeation chromatograph of 33kDa HAtoco10 monitored by fluorescence (295 Ex/330 Em) 
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2.3.7 Characterization of HAtoco by agarose electrophoresis 
 Effective size analysis of HAtoco in solution was next assessed by running samples on a 
1% (w/v) agarose gel with TAE, pH 8.3 running buffer and visualized using Stains-all. 33kDa 
HAtoco10 and unmodified polydisperse HA standards of increasing molecular weight (6.4, 33, 60, 
100, 200, 323, 622 and 2000 kDa) were equally loaded (2.5 g) onto the gel and ran with gel-
oriented for the negatively charge polymers to distribute towards the anode (Figure 2.12). HA 
standards were found to visualize and resolve well between 33 and 2000 kDa with retention of 
only 6.4 kDa HA undetermined. Electrophoresis of 33kDa HAtoco10 resulted in two distinct 
polydisperse populations, one at a similar retention to 33kDa HA and the other of a similar 
retention to 2000 kDa HA. These results support previous observations from visual and GPC 
experiments indicating 33kDa HAtoco10 forms a large particulate complex in solution similar in 
effective size to 2000 kDa HA and that significant unreacted base-polymer (33kDa) remains within 
the sample mixture. No polymer with visualized within the well or gel entrance suggesting 
electrophoresis within a 1% (w/v) agarose gel is sufficient to assess all sub-populations contained 














Figure 2.12: Agarose electrophoresis of 33kDa HAtoco10 (far left) against HA molecular weight 
standards (left to right; 6.4, 33, 60, 100, 200, 323, 622 and 2000 kDa) visualized with Stains-all. 
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2.3.8 HAtoco particle characterization by DLS and MFI 
 The distribution of HAtoco particle size was further investigated by DLS and MFI. DLS 
samples of 33kDa HAtoco10 dissolved in PBS, pH 7.4 to 10, 5, 2.5, 1.25 and 0.625 mg/ml and 
measured in five, 30 s acquisitions. The autocorrelation function was found to decay more rapidly 
with decreasing amounts of HAtoco suggesting a decrease in the particle size distribution upon 
dilution (Figure 2.13a). Relationship of the viscosity of HAtoco with concentration was estimated 
based on published rheology studies33 of the concentration effects on the viscosity of 2200 kDa 
HA at a shear rate of 91  7 sec-1 (Figure 2.13b, left).  Upper bound viscosity was set as the 
measured absolute viscosity reported in Figure 2.8 for 10 mg/ml HAtoco (16.4  0.1 cP) at a similar 
shear rate, while lower bound was set as 0.89 cP, the reported viscosity of PBS within the DLS 
software. Following adjustment of viscosity parameters, both number and intensity averaged 
diameters of the multimodal distribution analysis were found to decrease with increasing HAtoco 
concentration, opposite of the initial observations of the autocorrelation function alone. Intensity 
averaged diameter decreased exponentially from ~900nm at 0.625mg/ml to 150nm at 10mg/ml. 
Number averaged diameter decreased exponentially from ~20nm at 0.625 mg/ml to 4.5nm at 10 
mg/ml with the exception of the 2.5 mg/ml sample. Polydispersity was found to increase with 
HAtoco concentration indicating the development of a wider distribution of particle size at higher 
concentrations (Figure 2.13b, right). Similar results were seen when the intensity and number 
multimodal distributions are viewed versus concentration of HAtoco (Figure 2.13c). Both 
distributions were seen to decrease in diameter with increasing concentration. When distributions 
were combined, three populations of particles were resolved for the three highest concentrations 
(10, 5 and 2.5 mg/ml), one of high concentration and low particle size and two of lower 
concentration and higher particle size. Upon further dilution (1.25 and 0.625 mg/ml), the high 
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particle size populations were merged into one. These observations mirror the results seen 
following agarose electrophoresis of HAtoco where a low molecular weight population (small 
particle size) of heightened intensity (high quantity) and a high molecular weight population (large 
particle size) of lower intensity (low quantity) were resolved.  
 MFI analysis of 33kDa HAtoco10 at 1 mg/ml compared to unmodified 33kDa HA and 
200kDa HA at equal concentrations showed an order of magnitude increase in the quantities of >1 
m particles (Figure 2.14). This trend continued in subsequent bins of increasing particle size, but 
with an exponentially decreasing overall particle concentration. These results indicate a greater 
quantity of particles bordering the visible range (>100 m) exist following tocopherol substitution 
of HA. 
 
2.3.9 Thermal dependence of HAtoco colloidal stability 
 HAtoco colloidal stability was analyzed by monitoring static light scattering as a function 
of temperature. 33kDa HAtoco10 and 33kDa HA samples dissolved in PBS to 10 mg/ml were 
measured in triplicate in sealed quartz cuvettes from 10°C to 90°C (Figure 2.15). Unmodified HA 
exhibited no appreciable scattering throughout the temperature range tested and no visible 
difference in clarity post-heating indicating no aggregation of the polymer occurred. Heating of 
HAtoco resulted in a linear decrease in scattering from 25,000 kcps to 15,000 kcps which correlates 
to a reduction in particle size. Visual inspection of HAtoco solution post-heating showed no 
discernable difference in turbidity suggesting particles are resistant to temperature induced 






Figure 2.13: Dynamic light scattering of 33kDa HAtoco10 (10, 5, 2.5, 1.25 and 0.625 mg/ml) in 
PBS pH, 7.4. (a) Auto correlation function unzoomed (left) and zoomed (right)  showing variance 
in decay with concentration. (b) (left) Measured and estimated viscosity of serially diluted 33kDa 
HAtoco10 (10 mg/ml = 16.4 cP (measured at a shear rate of 86.25 sec-1), 5 mg/ml = 5.37 cP, 2.5 
mg/ml = 2.148 cP, 1.25 mg/ml = 1.4 cP and 0.625 mg/ml = 1 cP) and publisheda,33 viscosity versus 
concentration of 2200 kDa HA at a shear rate of 91  7 sec-1. (right) Viscosity adjusted MSD 
(multimodal size distribution) diameter and polydispersity with increasing HAtoco concentration. 
All samples measured in five acquisitions of 30 s each at room temperature with data represented 



















































































































































































as mean  SD. (c) Viscosity adjusted number (left) and intensity (right) weighted differential 
distribution (G(d)) versus diameter of varying concentrations of HAtoco. Distributions staggered 































Figure 2.14: MFI sizing of 33kDa HAtoco10, 33kDa HA and 200kDa HA at 1 mg/ml in PBS, pH 









































Figure 2.15: Colloidal stability of 33kDa HAtoco10, 1% (w/v) in PBS, pH 7.4  monitored by static 
light scattering with temperature ramped from 10 to 90°C. HAtoco samples were measured in 
triplicate with data represented as mean  SD. (Top) static light scattering count rate versus 
temperature for HAtoco and PBS samples. (Bottom) Images of triplicate quartz screw top cuvettes 
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2.3.10 In vivo release following subcutaneous injection 
 In order to assess the potential of HAtoco as a depot forming platform following 
subcutaneous injections, fluorescently labelled derivatives of both 33kDa HAtoco10 and 33kDa 
HA were synthesized and injected into the footpad of a BALB/c mouse and monitored for 
injection-site fluorescence for 60 days (Figure 2.16). Fluorescent intensity following injection for 
both derivatives was found to initially increase to a maximum around 4 days post injection for 
HAtoco and 1 day for HA suggesting a potential self-quenching mechanism upon initial injection. 
This had been observed in previous studies of fluorescent HA’s.35 Following the period of 
quenched fluorescent signal intensity, an exponential decay of fluorescent signal from both 
samples occurred with HAtoco signal significantly extended. Fluorescent intensity over 
background autofluorescence was measured, normalized and reported as integrated density (mean 
intensity x area) of the entire injected foot (Figure 2.17). Elimination phase of both release profiles 
were fitted using a one-phase decay non-linear regression with shared plateaus. HA fluorescent 
conjugate was found to release from the injection site with a half-life of 5 days while HAtoco 



















Figure 2.16: In vivo release of 33kDa HA-Cy7 or 33kDa HAtoco10-Cy7 fluorescent conjugates 
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Figure 2.17: In vivo release profiles of 33kDa HA-Cy7 and 33kDa HAtoco10-Cy7 conjugates 
remaining at the site of injection. Elimination phase fit using a one phase decay, non-linear 
regression with both plateaus constrained to equal values. Dotted-lines represent 95% confidence 

















































































































Sample t1/2 (days) 95% CI R2
24.8 19.3 to 34.7 0.9676
4.9 3.9 to 6.5 0.9119


























































































































































2.3.11 Chemical stability of HAtoco lysine linker at elevated temperatures 
 Chemical stability of the lysine linkage between HA and tocopherol within the 33kDa 
HAtoco10 conjugate was examined at 37°C in PBS, pH 6 at 1% (w/v). Samples were stored up to 
8 days before free tocopherol analysis using an adapted ethanol/hexane extraction followed by RP-
HPLC quantification. Potential to recover free tocopherol within the HAtoco matrix was validated 
by suspending known amounts of tocopherol to 500 g/ml in HAtoco, extracted and percent 
recovery assessed against a calibration curve of known tocopherol standards in ethanol (Figure 
2.18a and b). Percent recovery of five independently tested samples was found to be 84  14% 
(Figure 2.18c). Fresh HAtoco was found to contain 17 g/ml of free tocopherol and samples 
exposed to elevated temperature for up to 8 days did not show increases in free tocopherol content 
(Figure 2.18d). These results suggest the lysine linkage used to conjugate HA to tocopherol is not 
susceptible to chemical degradation/hydrolysis under the conditions tested. However, measurable 
free tocopherol content is present within the freshly dissolved HAtoco sample suggesting 
sequestered tocopherol not removed by dialysis purification exists at levels equal to ~2.4% of 
measured tocopherol content within 33kDa HAtoco10 by 1H NMR. 
 
2.3.12 Hyaluronidase Degradation of HAtoco 
 Enzymatic degradation of HAtoco by its natural endogenous enzyme hyaluronidase was 
analyzed by assessing size alterations with digestion time (up to 8 days) at elevated temperature 
(37°C). Size was monitored by agarose electrophoresis with visualization by Stains-all (Figure 
2.19). Unmodified 200kDa HA control was observed to degrade to a significantly lower molecular 
within 24 h when exposed to 50 g/ml of HAdase with no visible change in retention or band 
intensity without enzyme. In contrast, HAtoco was found to enzymatically degrade at a slower rate 
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with observable changes in size occurring between 2 and 8 days. HAtoco did not exhibit this extent 
of degradation without enzyme present at elevated temperature. No development of low molecular 
weight bands were seen upon apparent enzymatic degradation of HAtoco over 8 days suggesting 
development of molecular weights <33kDa which were not observable in previous agarose gels 
(Figure 2.12).  In addition, with the extension of electrophoresis and higher polymer loading, 
33kDa HAtoco10 separated into three distinct sub populations, one >33kDa, another >200kDa and 
a large effective size species >2000 kDa.  This pattern mirrors in distribution the three particle sub 
populations observed in the combined number and intensity multimodal distributions measured by 
















Figure 2.18: RP-HPLC analysis of free tocopherol following EtOH/Hexane extraction of 
thermally stressed 33kDa HAtoco10. (a) RP-HPLC chromatogram of tocopherol standards in 
absolute ethanol (1000 - 7.8 g/ml) monitored by UV-absorption at 280 nm. (b) Peak area of 
tocopherol standards versus concentration with linear regression. (c) RP-HPLC chromatogram of 
500 g/ml tocopherol spiked 33kDa HAtoco10, 1% (w/v), (N=5) with error bars equal to  SD, 
unspiked 33kDa HAtoco10, 1% (w/v) and unspiked PBS. (d) Measured free tocopherol within 
samples of 33kDa HAtoco10, 1% (w/v) in PBS, pH 6 following storage at 37°C for 0h, 1h, 4h, 8h, 
24h, 48h and 8 days (N = 1). 
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Figure 2.19: Agarose electrophoresis analysis of 33kDa HAtoco10 and 200kDa HA with or 
without 50 ug/ml hyaluronidase (HAdase) for 0h, 24h, 48h and 8 days at 37°C. (Far right) HA 
molecular weight standards (33, 2000 kDa). All samples visualized with Stains-all. Red arrows 
highlight three sub populations of HAtoco (1 = >33kDa, 2 = >200 kDa and 3 = >2000 kDa).  
 
















Novel drug delivery platforms which  effectively bind therapeutics with a range of 
physicochemical properties in addition to controlling the release upon administration are in 
development and of high interest. The flexibility of chemical and physical attributes of natural 
polysaccharides like  hyaluronic acid make these molecules ideal candidates for novel, targeted-
delivery and tailorable drug carriers. A  hyaluronic acid conjugate, hydrophobically modified with 
-tocopherol (HAtoco), was recently shown by our lab to effectively associate with a small 
molecule immunological agonist in a depot-like formation and sustain its immunotherapeutic 
effect locally upon subcutaneous administration.29 In this study, the development of the HAtoco 
platform is continued by further characterization of the physical and chemical properties and the 
capacity to deliver protein therapeutics in a controlled manner.  
 First, effects of altering the hyaluronic acid backbone molecular weight were explored by 
synthesizing HAtoco conjugates of 6.7, 33, 100 and 250kDa with a constant tocopherol 
substitution of 10 mol%. Similarly, the effects of altering  the degree of tocopherol substitution 
were explored by synthesizing conjugates of 5, 10, 15, 20 and 25 mol% with a constant molecular 
weight of 33kDa. There are challenges associated with quantitative 1H NMR analysis of chemical 
substitutions onto high molecular weight. For example, HA, including poor chemical shift 
dispersion leads to significant spectral overlap particularly within the backbone region 4.0ppm – 
3.1ppm. Additionally, as a result of erent high viscosity and associated concentrations required for 
adequate signal intensity, increasing polymer molecular weight leads to longer correlation 
(tumbling) times which gives rise to peak broadening and reduced spectral resolution.36 These are 
issues routinely associated with spectroscopy of high molecular weight polymers due to the back 
bone flexibility and dynamic motion. This can be partially overcome by conducting NMR at 
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elevated temperatures, however, HA is subject to rapid thermal degradation. Thus, this was not a 
viable option. Assuming complete removal of unreacted tocopherol within the dialysis purified 
conjugate, the degree of tocopherol substitution was assessed by 1H NMR using the peak area ratio 
of the commonly referenced16 -CH3 protons of the HA N-acetyl group and the -CH3 protons of the 
tocopherol phytyl side chain.  Clear broadening and weakening of the NMR spectrum was 
observed for both increases in tocopherol content and polymer molecular weight. This is likely 
due to the observed increases in solution viscosity upon tocopherol conjugation and incomplete 
dissolution. Reaction efficiencies increased from 62% to 85% with increasing tocopherol 
substitution and between 70% to-90% for increasing molecular weight polymer. Calculated 
substitutions at higher substitution degrees and molecular weights at which substantial peak 
broadening occurs likely suffer from low precision due to poor peak resolution. Overall, tocopherol 
substitutions above 10mol% and molecular weights above 33kDa were found to exhibit poor to 
incomplete dissolution, limiting  accurate 1H NMR analysis. .  
 Analysis of the binding capacity of HAtoco to protein therapeutics was assessed using the 
model protein BSA and binding isotherms created by monitoring the moment of the intrinsic 
tryptophan fluorescence. For a more representative comparison of HAtoco variants, disaccharide 
molar concentrations adjusted for average molecular weight of the disaccharide post-tocopherol 
substitution were plotted against fluorescent moment. No significant difference was observed in 
the binding capacity of the HAtoco variants to BSA, likely due to its known hydrophobicity.37 This 
hydrophobicity is beneficial when BSA is used as a blocking reagent within ELISA protocols or 
other assays requiring minimal non-specific binding.38 Unmodified HA did not produce any 
alteration of the BSA spectral moment, suggesting binding is specific to tocopherol moieties. 
Complete dissolution of 33kDa HAtoco10 at high concentrations coupled with its higher molecular 
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weight and thus potential to form a particle large enough (>100 nm)39, 40 to sustain delivery from 
an injection site without immediate clearance made it the best candidate for development moving 
forward. 
 The in vitro release of three model proteins (BSA, lysozyme and RNase) were assessed 
when mixed with the lead HAtoco candidate, 33kDa HAtoco10, compared to unmodified 33kDa 
HA. HAtoco was found to release protein at a 2-fold higher release half-life when fit to a one-
phase decay regression compared to HA for all model proteins tested. Large variability in the 
release half-life between model proteins in both formulations was apparent with BSA being much 
greater than lysozyme followed by RNase (BSA >> Lysozyme > RNase). A possible reason for 
this clear discrepancy is again likely due to the overall heightened surface hydrophobicity of BSA 
followed by lysozyme than the more polar RNase.41, 42  
Another possible difference in release between lysozyme and RNase, although small based 
on the 95% confidence intervals of the regression fit, could be explained by differences in their 
isoelectric points. Both proteins have a similar molecular weight, RNase at 13.7 kDa and lysozyme 
at 14.3 kDa, but lysozyme is significantly more basic with a pI of 11.3543 compared to a pI of 9.644 
for RNase. Release assays were examined in PBS at pH 7.4 with samples injected into concentrated 
(1% (w/v)) high molecular weight hyaluronan to simulate conditions found in the ECM of 
subcutaneous tissue. Neutral to slightly acidic conditions, due to the contributions  of hyaluronic 
acid, would induce a net positive overall charge for both proteins with lysozyme exhibiting a higher 
charge magnitude. Thus, differences in release could be due to the interaction of the more 
positively charged lysozyme dispersed into a hydrogel of anionic polymer compared to the slightly 
more neutral RNase. The extension of BSA release through an electrostatic interaction as opposed 
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to a hydrophobic one is less likely as BSA has an acidic pI (4.7)45 and would exhibit a net negative 
charge in the environment examined. 
Increases in the release of BSA with unmodified HA alone as well as the wide-error in 
release profiles for both HA and HAtoco samples could be a result of non-specific hydrophobic 
binding to surfaces within the release system such as the dialysis bag or plastic container, leading 
to skewed and variable measurements of released BSA concentration. In all release systems tested, 
except for BSA mixed with HAtoco, release plateaued at ~80% of the total protein initially loaded. 
Possibly explanations for this observation include again poor recovery due to non-specific binding, 
but also could be a result of protein degradation during the time-course of the assay. These results 
suggest HAtoco can effectively bind and release a range of protein therapeutics in a sustained 
manner following simulated injections.   
  The absolute viscosity and turbidity of 33kDa HAtoco10 were found to be significantly 
higher than the 33 kDa base polymer when measured using a cone plate rheometer and light 
scattering turbidimeter. Enhanced intramolecular and intermolecular  chain interactions  through 
the hydrophobic effect are likely responsible for increases in both viscosity and particle 
assembly.15  
 Agarose gel electrophoresis was found to be the most robust means of assessing the 
effective size of the hydrophobically modified HAtoco conjugate due to HPLC column inlet 
limitations that precluded GPC. Upon increased loading of HAtoco, agarose gels were able to 
resolve three distinct yet polydisperse populations within the purified conjugates. One lower 
molecular weight band associated with unreacted 33kDa HA and two higher molecular weight 
bands above 200 and 2000 kDa were observed. Development of multiple distinct sub populations 
of modified hyaluronan was an unexpected result. One theory explaining how this could have 
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developed is that during the reaction of hyaluronan and tocopherol, modified polymers began 
assembling into subvisible particles shielding themselves from further tocopherol conjugation 
except for surface exposed polymers, which continued to react. Upon particle relaxation under the 
initial ethanolic dialysis step and reformation upon exposure to fully aqueous systems, distinct 
populations of varying tocopherol substitutions were made, populations not distinguishable by 1H 
NMR substitution analysis.  To reduce system complexity in future reactions, extended reactions 
times coupled with an increased dialysis cut-off (100 kDa) need to be employed.  
Particle sizing experiments using DLS were in good agreement with the results from the 
agarose gel experiments in that three distinct populations of about 10, 70 and 200 nm diameter 
particles were resolved in samples of HAtoco dissolved at 10 mg/ml. The highest number of  
particles (~10 nm) corresponding to the expected size range of unreacted 33kDa HA.46 High 
molecular weight hyaluronic acid in the range of the HAtoco bands observed by agarose 
electrophoresis,  >200 kDa and >2000 kDa, have been measured by DLS to have radii of hydration 
of ~35nm and ~125nm respectively.47 These corresponding sizes are in good agreement to those 
measured by DLS for HAtoco. 
HAtoco particle size for all sub populations were observed to decrease with additional 
HAtoco in solution. In the most dilute solutions tested (1.25 and 0.625 mg/ml), the two largest sub 
populations merged into one. The effects of multiple scattering in such an uncorrected system can 
explain the trend toward smaller particle size with increasing turbidity of the sample.48 The fusion 
of populations however, cannot be explained by multiple scattering effects, but may be a result of 
concentration dependent equilibrium shift in which differentially substituted sub populations are 
driven to form new particles due to the low concentrations of HAtoco. 
 105 
 MFI analysis of particles nearing the visible range showed HAtoco increased the 
concentration of particles an order of magnitude for all sizes examined (up to 100 m). The overall 
decreasing concentration of particles with increasing particle size was consistent between HAtoco 
and unmodified HA. These results suggest that if used in the future for clinical applications, 
HAtoco may need to be properly filtered to eliminate larger size particles which may partially 
occlude fine injection needles (27-30 gauge). 
 The in vivo release of fluorescently labelled HAtoco showed a clear depot development 
mirroring that seen in previously published studies where HAtoco was reported to manifest a local 
depot formation in the delivery of an immunological agonist.29  HAtoco-Cy7 conjugates persisted 
at the subcutaneous injection site for over 60 days, while HA-Cy7 lasted for almost 30. The 
persistence of unmodified HA was longer than previously published findings of fluorescently 
labelled HA subcutaneously injected (<18 days),49 leading to the possibility that the degree of 
substitution of the unmodified HA was such that a self-assembling particle was made prolonging 
its release.  Increasing fluorescence intensity seen in both systems upon injection suggest some 
form of self-quenching, perhaps due to self-assembled particles, was initially occurring, but upon 
relaxation and release of the polymer from the site of injection quench was decreased. These results 
suggest that if association with a small molecule or protein therapeutic is strong enough to 
withstand in vivo conditions, release from the injection site may be extended for over two months. 
The extended residence time of the HAtoco conjugate is in line with the duration of cosmetic 
hyaluronic acid based dermal fillers (4-12 months) and much longer than the 24 h turnover of 
unmodified HA.50 
 Colloidal stability analysis of HAtoco through static light scattering with ramping 
temperature ramps up to 90°C indicated that the HAtoco particle linearly decreases in size with 
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temperature suggesting collapsing of the hydrophobic core. The increase in hydrophobic 
interactions with temperature is well documented51 and thus can explain the increase in strength 
of the hydrophobic core reducing the HAtoco particle size. Visual inspection of HAtoco after 
cooling indicated no apparent degradation of the colloid had occurred. Similarly, the covalent ester 
glycine linkage between HA and tocopherol was assessed at elevated temperatures (37°C) using 
an organic solvent extraction method coupled with RP-HPLC. No observable increase in free 
tocopherol content within the HAtoco system was observed over 8 days of incubation indicating 
limited to no hydrolysis of the ester linkage. Lastly, the stability of HAtoco was analyzed in the 
presence of the endogenous enzyme hyaluronidase. HAtoco was found to degrade to molecular 
weights unobservable on a 1% agarose gel within 8 days at 37°C compared to less than 24 h for 
unmodified HA. The decrease in hyaluronidase activity may be due to poor enzyme accessibility 
brought on by HAtoco particle formation or substitution of tocopherol to the HA backbone. 
 
2.5 Conclusions 
 Novel formulation platforms capable of modifying the release kinetics of a multitude of 
drug classes will continue to be a focus of pharmaceutical technical development. The recent 
description of an HA-tocopherol conjugate has shown its potential as a novel amphiphilic carrier 
capable of sustaining release of small molecule therapeutics following subcutaneous injection. In 
this study, the potential of HAtoco as a drug delivery platform was expanded to include the 
sustained delivery of protein therapeutics. In addition, the backbone molecular weight and 
tocopherol substitution were optimized, in vivo release kinetics determined with extensive 
chemical and physical characterization. Overall, these results show HAtoco can extend the release 
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of several model proteins particularly those of hydrophobic surface character such as BSA and is 
thermally and chemically stable with extended in vivo residence time. 
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Chapter III: Development and biophysical characterization 





The complement system is a major component of the innate immune system that assists in 
clearing pathogens and damaged cells. The complement proteins are a family of small inactive 
precursor proteins that circulate in the blood. Upon activation, the complement proteins undergo a 
cascade reaction that rapidly amplifies the host immune response. Complement-assisted pathogen 
death can occur through three known pathways: the classical, alternative and lectin pathways.1 
Each pathway is triggered by recognizing a specific pattern foreign to circulation. In the classical 
pathway, complement component C1 recognizes antibody, IgG or IgM, bound to a microbial 
surface leading to a cascade of protease activity and binding. This ultimately leads to the formation 
of the membrane attack complex (MAC). Once the MAC is formed, it creates a functional pore 
within the membrane of the target bacterium. The cell is then lysed and killed.2 
 Like many other systems of the innate and adaptive immune system, the complement 
system relies on complex feedback mechanisms. These feedback mechanisms are known as 
complement regulators which prevent inadvertent activation. The delicate balance between the 
identification of foreign substances versus self can be altered through a number of mechanisms. 
These mechanisms include age-related degeneration, genetic mutations and polymorphisms 
leading to a variety of disease manifestations.3 
 This type of dysregulation is central to diseases such as atypical hemolytic uremic 
syndrome (aHUS) and paroxysmal nocturnal hemoglobinuria (PNH); rare genetic mutations 
leading to complement activation and destruction of blood cells and subsequent damage to vital 
organs due to blood clot formation.4, 5 Symptoms of aHUS include acute kidney injury, proteinuria 
and hematuria. Symptoms of PNH include fatigue, hemolytic anemia and bone marrow 
hypocellularity.  Due to the high mortality rate in both diseases,6, 7 aggressive therapies were 
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initially employed including kidney transplantation and plasma replacement therapy for aHUS5and 
allogeneic bone marrow transplantations for PNH4. Both treatments resulted in minimal 
improvement in extension of life despite improved hematological outcomes. Eculizumab 
(Soliris, Alexion Pharmaceuticals) is a human monoclonal antibody which inhibits MAC 
formation by binding C5 of the complement cascade.8 Eculizumab was approved by the FDA in 
2007 for the treatment of patients with PNH9 and in 2011 for patients with aHUS10 to reduce 
complement mediated hemolysis. Treatment with Eculizumab has been shown to drastically 
reduce symptoms of both diseases while improving survival levels and is now considered a front-
line treatment. Recently, the FDA has approved Ravulizumab, Alexion’s BLA as a long-acting C5 
inhibitor,  for the treatment of PNH, with a target approval date in late 2019 for treatment of 
aHUS.11, 12 Ravulizumab has been shown to extend the required time between maintenance 
infusions from 2 weeks to 8 weeks with no inferiority in efficacy when compared to Eculizumab.13  
 Although the emergence of Eculizumab have been a drastic improvement in the treatment 
of PNH and aHUS, 25-35%14 of patients suffer from inadequate response to the drug. The 
inadequate response may be due to phagocytic clearance of opsonized C3-bound erythrocytes.15, 
16 Additionally, the annual treatment cost of Eculizumab is one of the most expensive 
pharmaceutical therapies to date,  projected at $500,000 annually.17 Given the large patient group 
who are non-responsive to current drugs and the high cost of treatment, there are strong incentives 
to develop improved treatments. 18 
 Coversin,  (Ornithodoros moubata complement inhibitor [OmCI], Nomacopan, Akari 
Therapeutics) is a second-generation C5 complement inhibitor. Coversin was originally 
discovered within the saliva of the O. moubata soft tick,  suppressing the host immune response 
during feeding.19 Like Eculizumab, Coversin also inhibits formation of the terminal MAC complex 
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through binding of the C5-component. However, C5 binding site differences between the antibody 
and Coversin20 could prove critical in patients with poor response to Eculizumab treatment.21 
Coversin is a lipocalin family protein comprised of 150 amino acids with a molecular weight of 
16.8kDa.It has been structurally described as a compact protein composed of a central eight-
stranded antiparallel -barrel and a carboxy-terminal -helix, similar to human plasma proteins of 
the same lipocalin family.22, 23  
 In phase II human trials for patients with PNH, Coversin demonstrated efficacy in all 
patients24, 25; however, lapses in sufficient complement inhibition were seen within 24 h following 
once-daily subcutaneous administrations. In an effort to extend the pharmacokinetics and 
minimize dosing frequency, Kuhn et. al examined a PASylated version of Coversin in which the 
N-terminus is recombinantly modified with the addition of a 600 residue peptide composed of 
proline, alanine and serine (PAS).14 Similar to the effects of protein PEGylation, PASylation has 
been shown to dramatically increase the hydrodynamic volume of a protein. PASylation thus 
reduces the renal clearance of the molecule due to the pore size limit of the glomerular 
membrane.26 The terminal plasma half-life of PASylated Coversin following subcutaneous 
injection was found to be 10.4 h compared to 0.2 h with i.v. infusion of unmodified Coversin. No 
reduction in complement inhibitory capacity was observed in C5 binding, in vitro MAC inhibition 
or model-PNH in vitro hemolysis assays with PASylated Coversin. 
 The pharmacokinetic improvements presented by PASylated Coversin are substantial. A 
complete phase I clinical trial is necessary to accurately examine the added benefits or potential 
harms of this alteration in humans, currently projected as a once weekly s.c. administration.27 
Added complexity to manufacturing and technical development due to the  alteration of the drug 
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must to be addressed to reduce the extremely high cost profile, burdening approved anti-
complement treatments.  
 Prolonging the pharmacokinetic profile of therapeutic proteins following parenteral 
injections has been a major topic of interest in the pharmaceutical research community, particularly 
since the approval of recombinant insulin in the early 1980s. Interest has grown rapidly as the 
prevalence of biological drugs continues to increase.28 In an effort to reduce healthcare costs and 
improve patient compliance, at home, self-administration subcutaneous injections has become the 
new target for proteins therapeutics requiring parenteral delivery.29 Multiple drug delivery 
strategies have been employed to create a platform in which a wide-range of biologics could be 
administered in a rate-controlled manner including PEGylation, polymeric microsphere 
encapsulation and liposomal formulations.30 One of the most promising strategies to date is the 
use of hydrogels to effectively control delivery of protein therapeutics without complex chemical 
or fabrication strategies which may negatively affect the desired biological effect or stability of 
the therapeutic.31 A recently reported32 nanogel using hyaluronic acid, an endogenous 
polysaccharide of the extra-cellular matrix, modified with vitamin E, has been shown to associate 
and extend delivery of intratumorally delivered TLR agonists through a depot-like formation. The 
following is an investigation the potential of this hyaluronic acid-vitamin E (hyaluronic acid-
tocopherol, HAtoco) platform to sustain delivery of unmodified Coversin following subcutaneous 
injection and its effects on protein structure and biological function. 
 




3.2 Materials and Methods 
3.2.1 Materials  
Coversin was supplied by Akari Therapeutics (London, UK) lyophilized in phosphate 
buffered saline. Sodium hyaluronate (HA) was obtained from Lifecore Biomedical (Chaska, MN). 
Alexa Fluor 647 NHS Ester, Rhodamine NHS Ester and SnakeSkin dialysis tubing were 
obtained from Thermo Fisher Scientific (Waltham, MA). Float-A-Lyzer G2 dialysis devices were 
purchased from Spectrum (Waltham, MA). PD-10 desalting columns with Sephadex G-25 resin 
were purchased from GE (Pittsburgh, PA). Complement System, Classical Pathway Wieslab 
ELISA kit COMPLCP310 was purchased from Euro Diagnostica (Malmö, Sweden). Chemical 
reagents including, (+)--tocopherol, 1-ethyl-3-(e-dimethylaminopropyl)carbodiimide 
hydrochloride (EDC-HCl), N,N’-dicyclohexylcarbodiimide (DCC), 4-dimethylaminopyridine 
(DMAP), N-(tert-butoxycarbonyl) glycine (Boc-Gly-OH), trifluoroacetic acid (TFA), 
tetrabutylammonium hydroxide (TBA-OH), and 1-hydroxybenzotriazole hydrate (HOBT-H2O) 
were purchased from Sigma Aldrich (St. Louis, MO). Solvents for flash chromatography, HPLC 
grade solvents and centrifugal filters were purchased from Fisher Scientific (Hampton, NH). 
 
3.2.2 Synthesis of hyaluronan-tocopherol conjugates 
Hyaluronan-tocopherol conjugates were synthesized as previously discussed in Chapter II 
(Scheme 1). Briefly, (+)--Tocopherol (Vitamin E) was coupled to a Boc-protected glycine 
through DCC/DMAP mediated esterification in anhydrous CH2Cl2 overnight. The reaction 
mixture was then cooled to -20°C and filtered. The filtrate was purified by silica gel flash 
chromatography using a hexane-ethyl acetate gradient and dried in vacuo. The product oil was 
dissolved in CH2Cl2, deprotected using TFA and subsequently dried in vacuo to remove solvent 
 120 
and TFA. The gray solid product was purified by silica gel flash chromatography using a hexane-
ethyl acetate gradient and again dried to yield a white solid product 1. Sodium hyaluronate (33 
kDa) was fully dissolved to 20 mg/ml in deionized water, followed by addition of Dowex AG 
50W-X8 resin (10-fold excess to HA by mass) and stirred overnight at 20°C. The resin was 
removed by filtration and filtrate was titrated with TBA-OH to pH 8-9, yielding a slightly pink 
solution. The HA-TBA solution was subsequently frozen and lyophilized to yield a pink-yellow 
cake 2. HA-TBA was then dissolved in DMF (20 mg/ml) and subsequently added to a mixture of 
1 (10 mg/ml), EDC-HCl (10 mg/ml) and HOBT-H2O (20 mg/ml) in DMF. The reaction mixture 
was stirred at 25°C overnight. The crude product was dialyzed (10 kDa MWCO) against 50% 
ethanol for 12 h, 150 mM sodium chloride for 12 h and water with three changes over 72 h. 






































































3.2.3 Subcutaneous-mimicking in vitro release 
Lyophilized Coversin was dissolved in deionized H2O to yield 10 mg/ml in PBS and 
subsequently added to an equal mass of lyophilized HAtoco, 33 kDa HA or 200 kDa HA by pipette. 
The Coversin/HAtoco solution was mixed overnight at 20°C protected from light. Float-A-Lyzer 
dialysis cassettes (300 kDa MWCO) were filled with 0.8 ml of 1% (w/v) 622 kDa sodium 
hyaluronate in PBS, pH 7.4 with 0.05% (w/v) NaN3 as an anti-microbial agent. Coversin/HAtoco 
mixture (0.2 ml) was pipetted into the HMW HA solution within the dialysis cassette and dialyzed 
against 30 ml of PBS, pH 7.4, 0.05% (w/v) NaN3 in a 50 ml conical centrifuge tube at 37°C while 
stirring. All release experiments were performed in triplicate. At predetermined intervals, the entire 
dialysate volume was replaced with fresh buffer and prior dialysate frozen at -80°C for future 
analysis. Percent Coversin released was determined by HPLC peak area against a standard curve. 
All chromatography was performed on a Shimadzu LC-2010C HT (Kyoto, Japan) with in-line UV 
detection (280 nm) using a Phenomenex Aeries 3.6 m Widepore XB-C18 column (250 x 4.5 mm) 
at 50°C. Gradient mobile phases were A: 9:1, H2O:Acetonitrile, 0.05% (v/v) TFA and B: 1:9, 
H2O:Acetonitrile, 0.05% (v/v) TFA with an elution gradient of 20-100% B over 6 min at a flow 






) ∗ 𝐷𝑖𝑎𝑙𝑦𝑠𝑎𝑡𝑒 𝑉𝑜𝑙𝑢𝑚𝑒 (𝑚𝑙)
𝐷𝑟𝑢𝑔 𝐼𝑛𝑖𝑡𝑖𝑎𝑙𝑙𝑦 𝐿𝑜𝑎𝑑𝑒𝑑 (𝑚𝑔)
∗ 100 
 
%𝐶𝐷𝑅𝑡 = %𝐷𝑅𝑡 + 𝐶𝐷𝑅𝑡−1 
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where %DRt = percentage of drug released at time (t); %CDRt-1 = cumulative drug released at time 
point prior to (t); %CDRt = cumulative drug released at time (t). Release profiles were fit using a 
one phase decay nonlinear regression in Prism 6 (Graphpad Software, San Diego, CA).  
 
3.2.4 In vivo subcutaneous release 
Alexa Fluor 647 NHS Ester (0.38 mg, 298 nmol) dissolved in 38 l of anhydrous DMSO 
was added to Coversin (1 mg, 59.6 nmol) while stirring in 100 l of 0.1 M NaHCO3, pH 8.8. 
Mixing continued for 2 h at 20°C protected from light. The product mixture was first purified over 
a PD-10 desalting column containing Sephadex G-25 resin with PBS, pH 7.4, as the mobile phase. 
The first three, 1 mL fractions eluted from the GPC column were pooled together and placed in a 
10 kDa MWCO dialysis cassette and dialyzed against PBS, pH 7.4, at 4°C with three bath changes. 
The final Coversin- Alexa Fluor 647 concentration was determined using the manufacturer’s 
instructions as described previously  in Chapter II with CF=0.03 and Amax=A650. Coversin- Alexa 
Fluor 647 conjugate (CovAF647) was diluted with PBS, pH 7.4, to 0.25 mg/ml and used to 
dissolve HAtoco or 200 kDa HA to 10 mg/ml. Coversin samples without dye were used to dissolve 
HAtoco and 200 kDa HA at the same concentrations and then used to dilute the fluorescent samples 
9-fold to reduce fluorescent intensity. All mixtures mixed overnight at 20°C, protected from light.  
All animal studies were approved by the University of Kansas Institutional Animal Care 
and Use Committee. Female BALB/c mice (16 – 20 g) were purchased from Charles River. Hair 
in the hind limbs was removed prior to treatment and imaging to reduce autofluorescence using 
depilatory cream. Mice (3 per group) were anesthetized with isoflurane and injected 
subcutaneously with 10 l of CovAF647/HAtoco, CovAF647/200kHA or CovAF647/PBS in the 
center of the hind footpad. Whole body fluorescent images were acquired at predetermined 
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timepoints using a CRi Maestro In Vivo Imaging System (Cambridge Research & Instrumentation, 
Inc., Woburn, MA) equipped with a 615-665 nm excitation bandpass filter and a 645 nm long pass 
emission filter. All images were acquired at a constant exposure of 1000 ms at 810 nm and equally 
scaled using the instrument software. Quantification of fluorescent intensity remaining at the 
injection site was performed by exporting images to ImageJ and adjusting threshold to a pixel 
intensity greater than 80 based on autofluorescent levels from naïve mice. Integrated density (mean 
intensity*area) of remaining fluorescent signal was measured from the area of the entire foot to 
the ankle.  
 
3.2.5 Fluorescence polarization binding isotherm 
Rhodamine NHS Ester (1.6 mg, 2.9 mol) was dissolved in 0.16 ml of anhydrous DMSO 
and added to Coversin (5 mg, 2.9 mol) while stirring in 0.5 ml of PBS, pH 7.4, for 2 h at 20°C 
protected from light. The product mixture was first purified by sequential dilution in PBS, pH 7.4, 
0.05% (w/v) NaN3, followed by concentration using a 3 kDa MWCO centrifugal filter, repeated 
three times. The concentrate was removed and purified further using a PD-10 desalting column 
containing Sephadex G-25 resin with PBS, pH 7.4, 0.05% (w/v) NaN3 as the eluent. The first three 
1 mL fractions eluted from the GPC column were pooled together and placed in a 3 kDa MWCO 
dialysis cassette and dialyzed overnight against PBS, pH 7.4, 0.05% (w/v) NaN3 at 4°C. 
Conjugation was verified by HPLC-ESI-TOF acquired on a Waters Synapt G2 (Milford, MA 
USA) hybrid  Quadrupole –Time of Flight mass spectrometer operated in MS mode and acquiring 
data with the time of flight analyzer.  The instrument was operated in resolution mode, 18K 
resolution.  The cone voltage was 45eV and Ar was admitted to the collision (trap) cell.  Spectra 
were acquired over the range of 500-3000 u.  Time to mass calibration was made with NaI cluster 
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ions acquired under the same conditions and lock mass corrected with an auxiliary sprayer 
presenting the doubly charged ion, 785.84265 m/2z, from Glu-fibrinogen peptide.  Lock mass 
spectra were acquired every 15s. “Zero” charge spectra were generated from the electrospray 
generated charge states using the “transform routine” in Masslynx post acquisition tools.  Spectra 
are centroided and adjacent ions are assigned as one charge state different and the rest of the charge 
state “train” are detected and assigned. For the final spectrum, regions of the continuum spectra 
are multiplied by charge state and shifted to the common mass by subtracting the appropriate 
number of protons (charge carriers). Samples were desalted on a C4 reverse phase column using a 
Waters nanoACQUITY UPLC. The column was 0.32mm x 50mm filled with Zora C4 5M 
particles. Mobile phase A was 0.08% (v/v) formic acid and B was 1:1:1, methanol:acetonitrile:2-
propanol. The desalting/ resolving gradient was 5 to 70% B in 20 min at 25l/min. 
 Product purity was assessed by RP-HPLC on a Shimadzu LC-2010C HT (Kyoto, Japan) 
with in-line UV detection (280 nm) and fluorescence (552 Ex./575 Em.) using a Waters 2475 Multi 
 Fluorescence Detector. Chromatography was performed on a Phenomenex Aeries 3.6 m 
Widepore XB-C18 column (250 x 4.5 mm) at 50°C. Gradient mobile phases were A: 9:1, 
H2O:Acetonitrile, 0.05% (v/v) TFA and B: 1:9, H2O:Acetonitrile, 0.05% (v/v) TFA with an elution 
gradient of 5-100% B over 7 min at a flow rate of 1.0 ml/min. 
 Final Coversin-Rhodamine concentration was determined using the NHS-Rhodamine 
manufacturer’s instructions with the following equation: 
 
𝑃𝑟𝑜𝑡𝑒𝑖𝑛 𝑐𝑜𝑛𝑐𝑒𝑛𝑡𝑟𝑎𝑡𝑖𝑜𝑛 (𝑀) =
𝐴280 − (𝐴𝑚𝑎𝑥 ∗ 𝐶𝐹)
𝜀
∗ 𝐷𝑖𝑙𝑢𝑡𝑖𝑜𝑛 𝑓𝑎𝑐𝑡𝑜𝑟 
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𝜀 = 22, 835 𝑀−1𝑐𝑚−1 
 Coversin-Rhodamine purified of unreacted dye was serially diluted with PBS, pH 7.4, 
0.05% (w/v) NaN3 to concentrations between 5 – 0.005 mg/ml and used to dissolve HAtoco or 33 
kDa HA to 10 mg/ml. All mixtures were allowed to mix overnight at 20°C, protected from light. 
Fluorescence polarization of all samples was measured in triplicate using a Biotek Synergy H4 
Hybrid Reader (Winooski, VT) equipped with a 485/20 nm excitation filter, 620/40 emission filter, 
and a 510 nm cutoff dichroic mirror. All measurements were made in triplicate and data fitted 
using a sigmoidal, 4PL non-linear regression in Prism 6.  
 
3.2.6 Intrinsic tryptophan fluorescence spectroscopy 
 Coversin steady-state intrinsic tryptophan fluorescence was acquired using a fluorescence 
plate reader manufactured by Fluorescence Innovations Inc. (Minneapolis, MN). Excitation 
wavelength was set at 295 nm coupled with a 310 nm long-pass dichroic mirror. Emission spectra 
was acquired from 300 – 400 nm with an integration time of 100 ms. Spectra was acquired from 
10 to 90°C with a 2.5°C step and 30 s equilibration time. Coversin in PBS/NaN3 at 0.25 mg/ml 
was used to dissolve lyophilized HAtoco or 33 kDa HA to 10 mg/ml and allowed to mix overnight 
at 20°C, protected from light. All samples were analyzed on a 384-well plate (n=6) with silicon oil 
added onto samples to avoid evaporation during heating. Spectra contributions from HAtoco, HA 
or buffer were subtracted from raw data and processed using Python to derive the spectral moment 
as a function of temperature as described by Wei et al.33 to calculate Coversin melting temperature 
(Tm). Melting curves were fitted using an asymmetric 5PL, non-linear regression with Prism 6.  
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3.2.7 Differential scanning calorimetry 
 Differential scanning calorimetry of Coversin (0.25 mg/ml) formulated in PBS/NaN3 alone 
or in HAtoco (10 mg/ml) was acquired in duplicate using a Malvern MicroCal VP-Capillary DSC 
(Malvern, UK). All samples were held in an autosampler tray at 4°C prior to analysis. Temperature 
was ramped from 20°C to 90°C with a scan rate of 1°C/min. Apparent transition temperature was 
derived using a non-two state equilibrium model with Origin 7.0 (OriginLab, Northhampton, MA).   
 
3.2.8 Fourier-transform infrared spectroscopy (FTIR) 
 FTIR spectra were collected using a Bruker Tensor 27 FTIR spectrometer (Billerica, MA) 
equipped with a liquid nitrogen cooled detector, KBr beam splitter and nitrogen purged 
interferometer. Coversin at 1, 2, 5, 10 and 30 mg/ml with and without HAtoco at 10 mg/ml were 
analyzed using a Bio-ATR cell with 250 scans between 4000 and 600 cm-1 with 4 cm-1 resolution.  
All measurements were made in triplicate at 25°C. Spectral contributions from HAtoco or PBS 
buffer alone were subtracted from sample spectra along with atmospheric water and baseline 
corrections using OPUS v6.5 (Bruker Optics, Billerica, MA). The absorbance spectrum of the 
Amide I region (1700-1600 cm-1) was normalized and deconvoluted using a mixed Gaussian and 
Lorentzian function resulting in 8 fitted peaks with the area corresponding to relative percentage 






3.2.9 Classical complement pathway inhibition 
 To assess the biological activity of Coversin upon release from the HAtoco formulation, 
selected samples from the subcutaneous-mimicking in vitro release assay described above were 
examined for classical complement pathway inhibition using the Complement System, Classical 
Pathway Wieslab ELISA kit. All reagent diluents and buffers were prepared fresh, autoclaved and 
filtered with a 0.2 m sterile filter, and all procedures were performed under aseptic conditions 
unless otherwise noted to prevent inadvertent microbial activation. Naïve human serum (positive 
control, PC) and heat-inactivated human serum (negative control, NC) were reconstituted, diluted 
and aliquoted for storage as directed by the manufacturer. Coversin standards were freshly 
dissolved in PBS, pH 7.4, 0.05% (w/v) NaN3 and serially diluted to a final concentration of 1000, 
200, 100, 75, 50 and 25 nM. Standards and release samples were plated into a low-protein binding 
Nunc 96-well polypropylene storage plate (Thermo Fisher Scientific) and diluted 10-fold with 
PC serum. Blank buffer diluted 10-fold in PC serum or NC serum was taken as the positive and 
negative controls, respectively. All samples and controls were incubated at room temperature for 
15 min to allow inhibitory activity to reach equilibrium. Following mixing and incubation, all 
samples were added to microplate wells precoated with the classical complement pathway 
precursor, human IgM, provided with the kit using a multi-channel pipette and incubated for 1 h 
at 37°C, covered to prevent evaporation. Following ELISA plate incubation, wells were aspirated 
by tapping onto sorbent paper and wash solution added for three total cycles. After the final 
aspiration, alkaline phosphatase anti-human C5b-C9 antibody conjugate was added to all wells 
and incubated, covered from light for 30 min at room temperature and washed as done previously. 
Lastly, p-nitrophenyl phosphate substrate was added to all wells, developed for 30 min at room 
temperature, covered from light and absorbance measured at 405 nm with pathlength correction 
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using a Biotek Synergy H1 Spectrophotometer. Absorbance data were fitted using a sigmoidal, 
4PL, non-linear regression with Prism 6. Release sample Coversin concentrations were determined 




3.3.1 Synthesis and characterization of HA-tocopherol 
 HAtoco was synthesized through the coupling of a Boc-protected glycine to the chromane 
ring hydroxyl of -tocopherol (vitamin E), deprotection and subsequent carbodiimide-mediated 
amidation to the carboxylate of 33 kDa sodium hyaluronate.  Unreacted tocopherol was removed 
by exhaustive dialysis against a 10 kDa MWCO membrane. Disaccharide molar substitution was 
characterized by 1H NMR using the peak area ratio of the HA N-acetyl protons (2.0 ppm) and the 
tocopherol side chain methyl protons (0.8 ppm) (Figure 3.1). Tocopherol substitution on a 
disaccharide molar basis was calculated at 7%. 
 
3.3.2 Extended release of Coversin by HA-tocopherol 
 In vitro subcutaneous-mimicking release of Coversin was examined by sampling release 
dialysate at predetermined time intervals and analyzing for protein concentration by correlating 
the peak area determined by RP-HPLC against known concentration standards (Figure 3.2).  
Release profiles of Coversin incubated with 33 kDa HAtoco10 (1% w/v), 33 kDa HA, 200 kDa 
HA in PBS, pH 7.4, 0.05% (w/v) NaN3 or buffer alone are shown in Figure 3.3. All release profiles 
were well fit by one-phase decay non-linear regression. Coversin formulated in PBS buffer alone 
was released from the high molecular weight hyaluronan matrix within the dialysis bag with a half-
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life of approximately 5.4 h (4.9 h – 6.1 h, 95% CI). 33 kDa HA and 200 kDa HA formulated 
Coversin exhibited a release half-life of 6.1 h (5.1 h – 7.5 h, 95% CI) and 4.4 h (3.4 h – 6.4 h, 95% 
CI) respectively. In comparison, Coversin formulated with HAtoco had a release half-life of 11.3 
h (9.9 h – 13.3 h, 95% CI).  Coversin was detected within the release dialysate for 9 days in the 

























Figure 3.1: 1H NMR of 33 kDa HA (above) and 33 kDa HA-tocopherol, 10 mol% disaccharide 













Figure 3.2: RP-HPLC chromatogram (280 nm) of Coversin standards vs. representative in vitro 
release sample (above) and calibration of curve of peak area at 14.0 min (below).  
 
 













































































































Figure 3.3: In vitro release of Coversin in 1% (w/v) test formulations of 33 kDa HA-tocopherol, 
10 mol% subst. (33 kDa HAtoco10), 200 kDa HA, 33 kDa HA or PBS alone. Release profiles fit 
using a one-phase decay non-linear regression. 
 




































Sample t1/2 (h) 95% CI R2
11.33 9.89 to 13.25 0.9748
4.42 3.37 to 6.39 0.9669
6.08 5.11 to 7.49 0.9633


















3.3.3 In vivo subcutaneous release 
 The in vivo release profile of Coversin complexed with HAtoco was assessed by 
subcutaneous administration of a fluorescently labeled Coversin at equal concentrations 
formulated within 33 kDa HAtoco10, 200 kDa HA or PBS into the hind limb footpad of female 
BALB/c mice (N=3). After injection, fluorescence at the injection site was monitored at 
predetermined intervals for 8 days. All images were taken at constant exposure times, equally 
threshold adjusted to minimize autofluorescent contributions (Figure 3.4) and reported as 
integrated density (mean intensity x area) and fit using a one-phase decay, non-linear regression 
(Figure 3.5). Coversin injected in PBS alone or 200 kDa HA had release half-lives of 6.7 h and  
5.3 h respectively and both had essentially no signal remaining at the injection site after 24 h. 
Coversin associated with HAtoco had a half-life of 10 h and persisted at the injection site for up 
to 3 days. Overall, the relative release half-lives of all the formulations patterned those found 
within the in vitro system with slight reductions likely due to the presence of endogenous 
hyaluronidase which is capable of degrading HAtoco and 200 kDa HA, pressure differences due 
to endogenous tissue pressure and walking contact and other hydrogel deterioration brought on by 
in vivo conditions not present within the model in vitro system. HAtoco again was able to provide 
a nearly 2-fold extended release of the Coversin protein with simple mixing and room temperature 











Figure 3.4: In vivo release of formulated Coversin-Alexa Fluor 647 conjugates injected 
subcutaneously into the hind footpad of a mouse immediately following injection (left), at peak 
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Figure 3.5: In vivo release profile of subcutaneously injected Coversin- Alexa Fluor conjugates 
formulated in 33 kDa HAtoco10, 200 kDa HA or PBS alone. Release data fit to a one phase 


































































Sample t1/2 (h) 95% CI R2
9.97 8.88 to 11.37 0.9824
5.29 4.88 to 5.77 0.9964
6.76 5.86 to 7.98 0.9763


























3.3.4 Assessing HAtoco and Coversin binding by intrinsic fluorescence 
 In order to assess Coversin association with HAtoco, intrinsic tryptophan (Trp) 
fluorescence was used to probe polarity of the tryptophan microenvironment. Emission spectra 
were collected between 300 – 400 nm formulated in 1% (w/v) 33 kDa HAtoco or 33 kDa HA 
(Figure 3.6). Emission spectra were also collected with increasing amounts of 33 kDa HAtoco10 
(Figure 3.7) and moment and area under the curve (intensity) plotted versus polymer concentration 
(Figure 3.8a, 3.8b). No shift in the Coversin emission moment was observed in either formulation 
as was seen in previous studies with model-protein BSA, suggesting no alteration in tryptophan 
environment polarity. However, clear decreases in overall peak area were observed with increasing 
amounts of HAtoco which were not observed with addition of unmodified HA. To assess the 
mechanism of fluorescent quenching using the Stern-Volmer equation (Equation 1), a plot of the 
ratio of the initial fluorescence intensity (F0) to the quenched fluorescence intensity (F) versus 
quencher concentration (Q) (Figure 3.8c) was made resulting in a non-linear, downward curved 
plot suggesting differing accessibilities of the three tryptophan residues within Coversin.35 Using 
a modified Stern-Volmer plot (Figure 3.8d) derived from equation 2, the y-intercept was taken as 
the inverse of the freely accessible fraction of the tryptophan fluorophore (fa) and was found to 
equal 23  3 %. Variance in the tryptophan accessibility suggests one reason why shifts in Coversin 
fluorescent moment are not observed with increasing HAtoco concentration as was seen in similar 
studies performed in Chapter II with model-protein BSA. Further experiments monitoring the 
fluorescent lifetime or absorption spectra with increasing HAtoco would be required in order to 
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Figure 3.6: Intrinsic tryptophan fluorescence spectra of Coversin (0.25 mg/ml) with and without 
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Figure 3.7: Coversin (0.25 mg/ml) intrinsic tryptophan fluorescence versus HAtoco concentration 
(10 mg/ml to 0.001 mg/ml), error bars represent SD (N=6). Spectra are equally offset for visual 
clarity. 
 












































Figure 3.8: (a) Coversin (0.25 mg/ml) intrinsic tryptophan fluorescence moment and (b) intensity 
versus HAtoco concentration, error bars represent SD (N=6). Black-dotted line represents average 
moment or intensity of Coversin alone with gray area equal to  SD (N=6). Intensity versus 
HAtoco concentration fit using a one-phase decay non-linear regression with Graphpad Prism 6, 
red-dotted line represents 95% confidence interval of fit. (c) Stern-Volmer plot and (d) modified 
Stern-Volmer plot with y-intercept depicting inverse fraction of accessible fluorophore (23  3 %). 
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3.3.5 Fluorescence polarization binding isotherm 
 To assess the binding stoichiometry of Coversin and HAtoco further, Coversin was 
fluorescently labelled to permit measurement of polarization changes when incubated with 
HAtoco. Free amines of Coversin were covalently modified with NHS-Rhodamine (NHS-Rh), 
purified by GPC and subsequently dialyzed. To verify conjugation of dye and to assess labelling 
degree, samples were analyzed by UPLC-ESI-MS, with +413.1 u corresponding to a rhodamine 
addition. Rhodamine substitution was verified and the degree of substitution was found to be a 
distribution of 1 to 4 dye molecules per protein (Figure 3.9). Purity of Coversin-Rhodamine 
(Coversin-Rh) was assessed by gradient RP-HPLC coupled with an in-line fluorescent detector. 
NHS-Rh standards were found to elute with a multiple peak pattern (Figure 3.10) possibly due to 
succinimidyl ester hydrolysis during storage. Purified Coversin-Rh was found to elute at a similar 
retention time (13.6 min) as unmodified Coversin standards (13.5 min). Assessment of peak area 
of free dye associated peaks and Coversin-Rh associated peaks suggests >95% purity of the 
Coversin-Rh conjugate from free dye.  
 After verifying dye conjugation and purity, 33 kDa HAtoco10 or 33 kDa HA were 
dissolved to 1% (w/v) in decreasing concentrations of Coversin-Rh, PBS, pH 7.4 and sample 
polarity was assessed by polarized fluorescent spectroscopy (Figure 3.11). No change in 
polarization occurred with increasing ratios of HA to Coversin (i.e. decreasing amounts of 
Coversin) or in buffer only controls. When formulated with HAtoco, Coversin was found to have 
a distinguishable increase in polarization beginning at about 1 mg/ml Coversin (10:1 (w/w), 
























Figure 3.10: RP-HPLC-Fluorescence-UV of GPC/dialysis purified Coversin-Rhodamine 























































































Figure 3.11: Fluorescence polarization versus concentration of Coversin-Rhodamine formulated 
in 1% (w/v) 33 kDa HAtoco10, 33 kDa HA or PBS alone (N=3). Polarization curves were fit using 



















































3.3.6 Coversin tertiary structure temperature stability assessment by intrinsic 
tryptophan fluorescence 
 The tertiary structure stability of Coversin in HAtoco was studied by monitoring intrinsic 
steady-state tryptophan (Trp) fluorescence with increasing temperature. Fluorescence was 
assessed at >90% bound Coversin based on stoichiometric ratios determined by fluorescence 
polarization binding isotherms. Raw spectra were background subtracted (Figure 3.12) and the 
moment, also known as mean spectral center of mass (MSM), was plotted against temperature 
(Figure 3.13). Upon heating, moment position for Coversin steadily increased from an initial 343 
nm at 10°C to 50°C, at which a significant thermal transition occurred with Tm at 60.3°C. HAtoco 
bound Coversin spectral moment remained relatively steady (340 nm) until an earlier thermal 
transition of 55.2°C. Both transitions exhibited a similar slope of change in the thermal transitions, 
but with post-transition moment of Coversin alone at 355 nm and in HAtoco at 349 nm. Overall, 
differences in tertiary structure thermal transitions suggests that when bound to the HAtoco 
platform, Coversin’s tertiary structure is significantly destabilized when compared to protein alone 














Figure 3.12: Intrinsic tryptophan spectra of Coversin at increasing temperature. Samples were 








Figure 3.13: Coversin (0.25 mg/ml) intrinsic tryptophan fluorescence moment versus temperature 
formulated with and without 33 kDa HAtoco10 at 1% (w/v). Melt curves fit with asymmetric 5-
parameter logistic fit non-linear regression and curve EC50 reported as the Tm (N=6). Data reported 
as mean  SD. 
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3.3.7 Differential scanning calorimetry 
 DSC was used to assess the overall conformational stability of binding Coversin to the 
HAtoco platform. One major transition was observed for both Coversin alone and when bound 
(>90%) to HAtoco (Figure 3.14). Slight differences in Tm values and thermograms were observed, 
mirroring findings of the fluorescent thermal melts. The Tm of Coversin alone was found to be 
~63.7°C while the Tm when bound to HAtoco was found to be ~60°C. A clear reduction in overall 
AUC of the thermogram, and thus the apparent Hcal, when bound to HAtoco was observed 
suggesting an overall reduction in the energy required to denature the protein present and thus an 
overall reduction in the presence of native state protein. Reductions in stored energy (apparent 
Hcal) and subsequently the equilibrium temperature between native and denatured protein (i.e. 
Tm) have been previously documented for partially unfolded proteins, and could be a result of 










Figure 3.14: Differential scanning calorimetry of Coversin (0.25 mg/ml) in PBS or formulated 






3.3.8 Fourier-transform infrared spectroscopy (FTIR) 
 The secondary structure of Coversin in solution and when bound to HAtoco were assessed 
by FTIR. Due to the limits of detection within the Amide I region of the FTIR spectra (Figure 
3.15), Coversin was measured down to 1mg/ml with and without HAtoco at 10 mg/ml. Absorption 
spectra within the Amide I region were atmospheric and baseline corrected, normalized and 
deconvoluted for component secondary structures using a mixed Gaussian and Lorentzian function 
(Figure 3.16). Clear differences can be seen in the absorption spectra of the HAtoco bound versus 
solution Coversin, particularly within the 1700 cm-1 to 1667 cm-1 range generally associated with 
-turn and -sheet contributions. After calculating component peak area contributions of the total 
absorption peak area, -turn and -sheet contributions in samples with increasing fraction of bound 
protein (i.e. lower protein concentrations) begin to deviate from the buffer only control (Figure 
3.17). At 1 mg/ml Coversin, -turn and -sheet cumulative contributions are 22% and 62% 
respectively, but when formulated with HAtoco they are 11% and 72% respectively (Figure 3.18). 
Alterations in these specific structures may be indicative of the particular location on the Coversin 

















































































































Figure 3.16: Deconvolution of Amide I FTIR absorption spectra for Coversin (1 mg/ml) in PBS 
(above) or Coversin (1mg/ml) with HAtoco (10 mg/ml) (below). 
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Figure 3.17: Component secondary structure contribution to overall secondary structure based on 
peak area of deconvoluted amide I band of Coversin (30 to 1 mg/ml) in PBS (above) or in HAtoco, 






































































Figure 3.18: Component secondary structure analysis of Coversin (1mg/ml) with and without 





































3.3.9 Classical complement pathway inhibition screening by ELISA 
 Retention of Coversin’s biological functionality after release from HAtoco was examined 
using a commercially available ELISA which measures the development of the terminal membrane 
attack complex (MAC) following initiation of the classical complement pathway. Complete 
inhibition was defined as the MAC formation in heat-inactived serum (NC) while full complement 
activity was defined as the MAC formation in naïve serum (PC). In vitro release samples of 
Coversin formulated in PBS alone (37h and 73h) or in HAtoco (33h and 73h) were mixed with 
naïve serum for 15 min prior to initiation of the classical complement cascade through exposure 
to IgM coating the wells of the micro-plate. All samples were found to provide full inhibition of 
the complement cascade (Figure 3.19). To determine the theoretical minimum amount of 
biologically active Coversin within each release sample, a dose-response curve of fresh Coversin 
was tested and the plateau of the sigmoidal response taken as the minimum concentration required 
to fully inhibit (MinCFI) the response within this system which was determined to be 24.6 nM. The 
theoretical minimum biological protein content of each sample is dependent on the concentration 
tested within all samples. Completely biologically active protein may exist within each sample; 
however, it is important to note that due to the small dynamic range and limited plate capacity, 
100% inhibition does not equate to 100% retainment of biologically active protein content. With 
these caveats in mind, retainment of biologically active protein following 73 h of release both 
within the PBS control and within the HAtoco formulated samples is surprising based on 
documented lapses in biological activity in vivo within 24 h post-subcutaneous delivery in human 
clinical trials. These results coupled with in vitro and in vivo release profiles suggest HAtoco is 
capable of extending the delivery of Coversin following subcutaneous injection and that Coversin 
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Figure 3.19: (Above) Coversin dose response complement classical pathway MAC inhibition by 
ELISA with bounds determined by heat-inactivated serum (PC) and naïve serum (NC) responses. 
Minimum Coversin concentration required for 100% inhibition was found to be 24.6 nM by non-
linear regression of the Coversin standard curve. Orange dotted-line represent 95% confidence 
interval of non-linear regression. (Below) aComplement inhibition activity of in vitro release 
samples formulated in PBS only (37h, 73h release time points) or HAtoco, PBS (33h, 73h time 
points) determined by PC and NC bounds (equation 1). bIn order to assess the minimum percentage 






































PBS Only 37 100.1 ± 0.03 87.0 ± 6.2 28.4 ± 2.1
73 100.5 ± 0.35 27.9 ± 5.4 90.4 ± 17.0
HAtoco, PBS 33 100.0 ± 0.30 113.0 ± 8.9 21.9 ± 1.6
73 99.8 ± 0.03 76.4 ± 3.0 32.2 ± 1.3
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protein by RP-HPLC was compared to the measured concentration of fresh protein required for 






















 Unwanted overactivation of the complement system underlies the core of a number of life-
threatening diseases such as PNH and aHUS, which until recently did not have any available 
pharmacological treatment. Fortunately, with the development of potent complement system 
inhibitors such as Eculizumab, many lives have been saved and the quality of these patients’ lives 
dramatically altered. However, available pharmacotherapies are limited, ineffective in many 
patients, and costly. There is a substantial need to develop new medicines to address and expand 
treatment efficacy within this patient population, while simultaneously reducing the cost 
associated with treatment to those who respond to currently approved drugs. 
 Coversin is a second-in-class C5-complement inhibitor shown to effectively treat patients 
with PNH and is currently being evaluated in multiple clinical trials. Based on initial human 
clinical data, a clear need exists for improved technical development of Coversin, because as it is 
currently formulated, greater than once-daily dosing would be required to maintain necessary 
complement inhibition. To reduce the burden associated with multiple daily injections, a simple 
release platform which effectively extends release of the therapeutic beyond 24 h and which does 
not compromise its biological activity is desperately needed. 
 A recently reported hyaluronic-Vitamin E (HAtoco) conjugate was shown to effectively 
release small molecule TLR agonists through a depot-like effect following intratumoral injections, 
and as a consequence was shown to effectively reduce tumor size in both a mice xenograft trial 
and pilot canine study.32 In this study, HAtoco is examined for its capacity to sustain delivery of 
biologically active Coversin following subcutaneous injections and its effects on the protein’s 
structural characteristics and thermal stability. 
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 Following the synthesis and purification of 33 kDa HAtoco with a 10 mol% disaccharide 
substitution, the extended release of Coversin was initially evaluated using an in vitro system 
composed of a molecular weight dialysis bag and high molecular weight hyaluronan intended to 
mimic the environment of a subcutaneous injection site.36 Against buffer alone and viscosity-
matched controls (200 kDa HA), HAtoco at equal mass to loaded Coversin, extended release by 
greater than 2-fold by the release half-life and depot duration. Similarly, under in vivo conditions, 
Coversin labelled with fluorescent dye was loaded into the HAtoco matrix and release was 
extended nearly 2-fold by half-life and greater than 2-fold by depot duration. These results suggest 
HAtoco at ratios up to 1:1 Coversin:HAtoco (m/m) will extend release of the therapeutic to a level 
where multiple daily injections would not be required. Instead, potentially bi-weekly injections 
based on comparable release half-lives seen in PASylated coversin preclinical pharmacokinetic 
data and human projections are possible.14, 27  Complications to this claim include the 
translatability of both in vitro and fluorescently labeled in vivo data towards a therapeutic 
pharmacokinetics profile and also the high dosing requirements currently in use at the clinic. 
Current clinical dosing regimens include a single ablating dose of 0.57 mg/kg with daily repeat 
maintenance doses set initially at 25% of the ablating dose.25 To dose an average male patient (90 
kg x 0.57mg/kg = 51.3 mg) subcutaneously with a volume of less than 1.5 ml (51.3 mg/1.5 ml = 
34.2 mg/ml) to limit pain, a ratio of 3.42:1 (m/m), Coversin:HAtoco (i.e. 34.2 mg Coversin:10 mg 
HAtoco per ml) would be required for the ablating dose based on current viscosity limits 
syringeable through a 30-gauge needle (<50 cP).37 The viscosity of the 10 mg/ml HAtoco used in 
this study is equal to 16.4 cP as discussed in Chapter II.  
Based on binding isotherms determined by intrinsic tryptophan fluorescence signal 
quenching (Figure 3.8) and fluorescence polarization (Figure 3.10), >90% binding of Coversin to 
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HAtoco occurs near a ratio of 40:1 (m/m). This suggests the greatest increase in half-life release 
would be seen at ratios much lower than the 1:1 (m/m) tested in the in vitro assay, however when 
such ratios were used within the in vivo assay no increase in release half-life was observed. It is 
possible that in vivo factors such as higher surfactant concentrations could have weakened the 
binding between the HAtoco matrix and Coversin even at these lower ratios subsequently 
decreasing the observed release half-life. 
Reductions in the melting temperature (Tm) of Coversin when >90% bound to HAtoco 
measured by both DSC and intrinsic tryptophan fluorescence, suggests destabilization of the 
Coversin native structure when associated with the HAtoco matrix, perhaps due to surface 
adsorption to the tocopherol moieties. It has been shown that hydrophobically-driven surface 
adsorption is energetically favorable due to the negative entropic contribution (+S) to the Gibbs 
free energy when water or counter ions are excluded from the protein surface upon binding.38 
Energetic effects on protein binding are largely dependent on the protein and surface of interest 
and their particular characteristics. BSA was reported to bind Alhydrogel through apolar driven 
interactions and was found to have a considerably altered calorimetric thermogram with transitions 
occurring up to 39°C lower than the native protein.39 BSA is however known to contain a large 
hydrophobic binding site which has shown the ability to self-associate40 and may represent the 
extreme of such binding when coupled with in vitro release data from Chapter II where HAtoco 
bound BSA released less than 20% over 25 days.  
The lipocalin family of proteins, of which Coversin (OmCI) is a member, are known to 
bind a wide-range of small hydrophobic ligands as part of their natural function as extracellular 
transport proteins.41 These ligands include molecules with critical biological function such as long-
chain fatty acids, triacylglycerols, steroids and recently vitamin A and E (e.g. (+)--tocopherol).23, 
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42 Vitamin E in its water-soluble form of D--tocopheryl polyethylene glycol succinate (TPGS), 
was recently shown to decrease antibiotic resistance in vitro by binding the lipocalin protein BcnA 
produced by the gram-negative bacteria Burkholderia cenocepacia and subsequently inhibiting its 
function as a global extracellular mechanism of antimicrobial resistance.43 Similarly, Coversin has 
been shown to bind the fatty acid derivatives ricinoleic acid, palmitic acid, stearic acid and 
tetraethylene glycol diethylether within the lipocalin conserved, central, eight-stranded antiparallel 
-barrel.22 This structure, known as the lipocalin fold or pocket, is widely accepted as the primary 
binding region of hydrophobic ligands for all proteins of the lipocalin family. Similar to our results 
seen upon HAtoco binding to Coversin, structural studies on the effects of hydrophobic ligand 
binding to the -barrel pocket within human tear lipocalin protein have shown reversible increases 
in -sheet structure.44-46 In addition, extensive x-ray crystallography, NMR and site-directed 
mutagenesis studies coupled with docking models have shown that the therapeutic inhibition of 
C5 by Coversin (OmCI) occurs through binding on the opposite face from the characteristic -
barrel pocket.20, 22 These studies have also found that Coversin is capable of binding its other 
therapeutic ligand, the proinflammatory leukotriene LTB4 which binds within the -barrel fold, 
simultaneous to binding C5 in a noncooperative manner.47, 48 Overall, these results coupled with 
the observed preservation of the C5 inhibitory function of Coversin upon release from HAtoco 
suggest that the tocopherol moieties of HAtoco bind to Coversin within the characteristic -barrel 
ligand pocket without perturbation of the C5 binding site on its opposite face. Further studies are 
required to assess the reversibility in secondary structure alterations within the -barrel pocket 





 Coversin, a second-in-class C5 inhibitor, has shown promise in the continued development 
of the breakthrough therapies inhibiting complement activation for patients suffering from PNH 
and aHUS. In an effort to reduce the injection frequency of Coversin, HAtoco was shown to extend 
the release of Coversin in both in vitro and in vivo models. In addition, C5 inhibitory activity was 
observed following release of Coversin from the HAtoco matrix for at least 73 h. Structural studies 
suggest Coversin binding to HAtoco occurs through hydrophobically driven surface adsorption 
with binding likely occurring within the characteristic lipocalin -barrel opposite the Coversin-C5 
interface.  Overall, HAtoco may be considered as a simple platform capable of extending the 
release of biologically active Coversin following subcutaneous injection. Extension of the release 
would reduce dosing frequency and thus improve Coversin’s potential as a cheaper, efficacious 
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